CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitor
Accession: CHEBI:76848
browse the term
Definition: An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that interferes with the activity of any such enzyme that uses a disulfide as acceptor (EC 1.17.4.*).
Synonyms: related_synonym: EC 1.17.4.* inhibitor; EC 1.17.4.* inhibitors; oxidoreductase acting on CH or CH2 with a disulfide as acceptor (EC 1.17.4.*) inhibitors
G
A2m
alpha-2-macroglobulin
increases expression
ISO
Gemcitabine results in increased expression of A2M protein
CTD
PMID:20531411
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
G
Abcb1a
ATP binding cassette subfamily B member 1A
decreases expression
ISO
Gemcitabine results in decreased expression of ABCB1 mRNA; Gemcitabine results in decreased expression of ABCB1 protein
CTD
PMID:35063459
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
G
Acp3
acid phosphatase 3
decreases expression
ISO
Gemcitabine results in decreased expression of ACP3 protein
CTD
PMID:20531411
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
G
Adam17
ADAM metallopeptidase domain 17
multiple interactions
ISO
ADAM17 protein promotes the reaction [Gemcitabine results in increased cleavage of AREG protein]
CTD
PMID:20726858
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
G
Adipoq
adiponectin, C1Q and collagen domain containing
increases expression
ISO
Gemcitabine results in increased expression of ADIPOQ protein
CTD
PMID:20531411
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
G
Afp
alpha-fetoprotein
decreases expression
ISO
Gemcitabine results in decreased expression of AFP protein
CTD
PMID:20531411
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
G
Agpat2
1-acylglycerol-3-phosphate O-acyltransferase 2
decreases expression
ISO
Gemcitabine results in decreased expression of AGPAT2 mRNA
CTD
PMID:17039268
NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
G
Akt1
AKT serine/threonine kinase 1
affects response to substance multiple interactions
ISO
AKT1 protein affects the susceptibility to Gemcitabine [Gemcitabine co-treated with licoricidin] results in decreased phosphorylation of AKT1 protein; [licoricidin co-treated with Gemcitabine] results in decreased phosphorylation of AKT1 protein
CTD
PMID:15867245 PMID:29782821
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
G
Aldh1a1
aldehyde dehydrogenase 1 family, member A1
multiple interactions decreases expression
ISO
sulforaphane promotes the reaction [Gemcitabine results in decreased expression of ALDH1A1 protein]
CTD
PMID:20940707
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
G
Aldh1a3
aldehyde dehydrogenase 1 family, member A3
increases expression
ISO
Gemcitabine results in increased expression of ALDH1A3 mRNA
CTD
PMID:17039268
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
G
Aldh6a1
aldehyde dehydrogenase 6 family, member A1
increases expression
ISO
Gemcitabine results in increased expression of ALDH6A1 mRNA
CTD
PMID:17039268
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
G
Anapc1
anaphase promoting complex subunit 1
increases expression
ISO
Gemcitabine results in increased expression of ANAPC1 mRNA
CTD
PMID:17039268
NCBI chr 3:115,850,117...115,930,259
Ensembl chr 3:115,850,185...115,930,273
G
Ank3
ankyrin 3
increases expression
ISO
Gemcitabine results in increased expression of ANK3 mRNA
CTD
PMID:17039268
NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
G
Ankrd1
ankyrin repeat domain 1
increases expression
ISO
Gemcitabine results in increased expression of ANKRD1 mRNA
CTD
PMID:17039268
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
G
Antxr1
ANTXR cell adhesion molecule 1
affects expression
ISO
Gemcitabine affects the expression of ANTXR1 mRNA
CTD
PMID:17039268
NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232
G
Apcs
amyloid P component, serum
decreases expression
ISO
Gemcitabine results in decreased expression of APCS protein
CTD
PMID:20531411
NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298
G
Apoh
apolipoprotein H
increases expression
ISO
Gemcitabine results in increased expression of APOH protein
CTD
PMID:20531411
NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329
G
Ar
androgen receptor
multiple interactions
ISO
Gemcitabine binds to and results in decreased activity of AR protein
CTD
PMID:25752796
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Areg
amphiregulin
multiple interactions decreases response to substance increases cleavage increases expression
ISO
ADAM17 protein promotes the reaction [Gemcitabine results in increased cleavage of AREG protein] AREG protein results in decreased susceptibility to Gemcitabine Gemcitabine results in increased expression of AREG protein
CTD
PMID:20726858
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
G
Arf1
ADP-ribosylation factor 1
decreases expression
ISO
Gemcitabine results in decreased expression of ARF1 mRNA
CTD
PMID:17039268
NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
G
Arnt
aryl hydrocarbon receptor nuclear translocator
increases expression
ISO
Gemcitabine results in increased expression of ARNT mRNA
CTD
PMID:20103597
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
G
Atf3
activating transcription factor 3
increases expression
ISO
Gemcitabine results in increased expression of ATF3 mRNA
CTD
PMID:17039268
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
G
Axin2
axin 2
affects expression
ISO
Gemcitabine affects the expression of AXIN2 mRNA
CTD
PMID:20103597
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
G
Axl
Axl receptor tyrosine kinase
multiple interactions
ISO
AXL protein promotes the reaction [Warfarin results in increased susceptibility to Gemcitabine]
CTD
PMID:26206560
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions
ISO
[alvocidib co-treated with Gemcitabine] results in increased expression of BAX protein; [ICI 118551 co-treated with Gemcitabine] results in increased expression of BAX protein; [Mastic Resin co-treated with Gemcitabine] results in increased expression of BAX protein; [TNFSF10 co-treated with Gemcitabine] affects the localization of BAX protein
CTD
PMID:15770523 PMID:17671697 PMID:20523344 PMID:21570961
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Bcl2
BCL2, apoptosis regulator
decreases expression multiple interactions
ISO
Gemcitabine results in decreased expression of BCL2 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of BCL2 protein [alvocidib co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Aminophylline co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [ICI 118551 co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Mastic Resin co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Theophylline co-treated with Gemcitabine] results in decreased expression of BCL2 protein; Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BCL2 mRNA]; Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BCL2 protein]; U 0126 inhibits the reaction [Gemcitabine results in decreased expression of BCL2 protein]
CTD
PMID:15476743 PMID:15645133 PMID:15770523 PMID:16929163 PMID:17440100 PMID:20523344 PMID:21570961 More...
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Bcl2l1
Bcl2-like 1
multiple interactions decreases expression
ISO
Gemcitabine inhibits the reaction [Fluorouracil affects the expression of BCL2L1 mRNA]; Gemcitabine inhibits the reaction [Fluorouracil affects the expression of BCL2L1 protein] Gemcitabine results in decreased expression of BCL2L1 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of BCL2L1 protein
CTD
PMID:15476743 PMID:16929163 PMID:17440100
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
G
Bcl2l11
Bcl2-like 11
increases expression
ISO
Gemcitabine results in increased expression of BCL2L11 mRNA
CTD
PMID:17039268
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
G
Bcl6
BCL6, transcription repressor
increases expression
ISO
Gemcitabine results in increased expression of BCL6 mRNA
CTD
PMID:17039268
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
G
Bdnf
brain-derived neurotrophic factor
decreases expression
ISO
Gemcitabine results in decreased expression of BDNF protein
CTD
PMID:20531411
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
G
Bid
BH3 interacting domain death agonist
increases cleavage
ISO
Gemcitabine results in increased cleavage of BID protein
CTD
PMID:14750167
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
G
Birc2
baculoviral IAP repeat-containing 2
increases expression
ISO
Gemcitabine results in increased expression of BIRC2 mRNA
CTD
PMID:17039268
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
G
Birc3
baculoviral IAP repeat-containing 3
multiple interactions affects expression
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of BIRC3 protein Gemcitabine affects the expression of BIRC3 mRNA
CTD
PMID:17039268 PMID:17440100
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
G
Birc5
baculoviral IAP repeat-containing 5
multiple interactions decreases expression
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of BIRC5 protein Gemcitabine results in decreased expression of BIRC5 protein Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BIRC5 mRNA]; Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BIRC5 protein]
CTD
PMID:16929163 PMID:17440100 PMID:38000456
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
G
Bnip3l
BCL2 interacting protein 3 like
increases expression
ISO
Gemcitabine results in increased expression of BNIP3L mRNA
CTD
PMID:17039268
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
G
Braf
B-Raf proto-oncogene, serine/threonine kinase
decreases expression
ISO
Gemcitabine results in decreased expression of BRAF mRNA
CTD
PMID:20103597
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
G
Brca1
BRCA1, DNA repair associated
decreases response to substance increases expression
ISO
BRCA1 results in decreased susceptibility to Gemcitabine Gemcitabine results in increased expression of BRCA1 mRNA
CTD
PMID:20103597 PMID:21771338
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
G
Casp3
caspase 3
increases cleavage increases expression increases activity multiple interactions
ISO
Gemcitabine results in increased cleavage of CASP3 protein Gemcitabine results in increased expression of CASP3 protein modified form Gemcitabine results in increased activity of CASP3 protein [10-propargyl-10-deazaaminopterin co-treated with Gemcitabine] results in increased activity of CASP3 protein; [Curcumin co-treated with Gemcitabine] results in decreased expression of CASP3 protein [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Gemcitabine] affects the activity of CASP3 protein; [3-(4-methylphenylsulfonyl)-2-propenenitrile co-treated with Gemcitabine] affects the activity of CASP3 protein; [alvocidib co-treated with Gemcitabine] results in increased cleavage of CASP3 protein; [Calcitriol co-treated with Gemcitabine] results in increased expression of CASP3 protein; [Gemcitabine co-treated with TNFRSF10B] affects the activity of CASP3 protein; [Vorinostat co-treated with Gemcitabine] results in increased activity of CASP3 protein; Gemcitabine results in increased activity of and results in increased cleavage of CASP3 protein; Gemcitabine results in increased expression of and results in increased activity of CASP3 protein; licoricidin promotes the reaction [Gemcitabine results in increased activity of CASP3 protein]; licoricidin promotes the reaction [Gemcitabine results in increased expression of and results in increased activity of CASP3 protein]; PIF1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP3 protein]; Quercetin promotes the reaction [Gemcitabine results in increased activity of CASP3 protein]; SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP3 protein]
CTD
PMID:12479703 PMID:15476743 PMID:15726400 PMID:15770523 PMID:16153448 PMID:16467107 PMID:17159604 PMID:17440100 PMID:18089714 PMID:20299819 PMID:20699664 PMID:20798217 PMID:21418860 PMID:26050647 PMID:29782821 PMID:37183367 More...
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Casp6
caspase 6
multiple interactions
ISO
[Calcitriol co-treated with Gemcitabine] results in increased expression of CASP6 protein
CTD
PMID:20699664
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
G
Casp8
caspase 8
increases cleavage multiple interactions increases activity
ISO
Gemcitabine results in increased cleavage of CASP8 protein [Calcitriol co-treated with Gemcitabine] results in increased expression of CASP8 protein; [Gemcitabine co-treated with TNFRSF10B] affects the activity of CASP8 protein; [TNFSF10 co-treated with Gemcitabine] results in increased activity of CASP8 protein; Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein; SFN protein inhibits the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]; YAP1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein] Gemcitabine results in increased activity of CASP8 protein
CTD
PMID:12479703 PMID:14750167 PMID:17159604 PMID:17671697 PMID:18089714 PMID:20699664 PMID:26894857 More...
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
G
Casp9
caspase 9
multiple interactions increases activity increases cleavage
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of CASP9 protein Gemcitabine results in increased activity of CASP9 protein Gemcitabine results in increased cleavage of CASP9 protein [Calcitriol co-treated with Gemcitabine] results in increased expression of CASP9 protein; Quercetin promotes the reaction [Gemcitabine results in increased activity of CASP9 protein]; SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP9 protein]
CTD
PMID:12479703 PMID:15476743 PMID:15726400 PMID:17159604 PMID:17440100 PMID:20699664 PMID:21418860 PMID:26050647 More...
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
G
Ccl2
C-C motif chemokine ligand 2
decreases expression
ISO
Gemcitabine results in decreased expression of CCL2 protein
CTD
PMID:20531411
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
G
Ccl20
C-C motif chemokine ligand 20
increases expression
ISO
Gemcitabine results in increased expression of CCL20 mRNA
CTD
PMID:17039268
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
G
Ccl3
C-C motif chemokine ligand 3
increases expression
ISO
Gemcitabine results in increased expression of CCL3 protein
CTD
PMID:20531411
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
G
Ccnb1
cyclin B1
decreases expression increases expression
ISO
Gemcitabine results in decreased expression of CCNB1 mRNA Gemcitabine results in increased expression of CCNB1 protein
CTD
PMID:11504793 PMID:20103597
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnd1
cyclin D1
multiple interactions decreases expression
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of CCND1 protein Gemcitabine results in decreased expression of CCND1 mRNA; Gemcitabine results in decreased expression of CCND1 protein Celecoxib promotes the reaction [Gemcitabine results in decreased expression of CCND1 protein]
CTD
PMID:16060994 PMID:17039268 PMID:17440100
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Ccng2
cyclin G2
increases expression
ISO
Gemcitabine results in increased expression of CCNG2 mRNA
CTD
PMID:17039268
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
G
Cd274
CD274 molecule
multiple interactions
ISO
[Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 protein]
CTD
PMID:32894642
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
G
Cd40
CD40 molecule
decreases expression
ISO
Gemcitabine results in decreased expression of CD40 mRNA; Gemcitabine results in decreased expression of CD40 protein
CTD
PMID:17039268 PMID:20531411
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
G
Cd40lg
CD40 ligand
decreases expression
ISO
Gemcitabine results in decreased expression of CD40LG protein
CTD
PMID:20531411
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
G
Cd44
CD44 molecule
affects expression
ISO
Gemcitabine affects the expression of CD44 mRNA
CTD
PMID:35063459
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
G
Cda
cytidine deaminase
affects response to substance multiple interactions
ISO
CDA protein affects the susceptibility to Gemcitabine [Crizotinib results in decreased expression of CDA protein] which results in increased susceptibility to Gemcitabine; CDA protein affects the susceptibility to [Gemcitabine co-treated with Mitomycin]; CDA protein affects the susceptibility to [Gemcitabine co-treated with Oxaliplatin]
CTD
PMID:18728667 PMID:22973962
NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231
G
Cdc25c
cell division cycle 25C
multiple interactions
ISO
[Gemcitabine co-treated with ON 01910] results in decreased expression of CDC25C protein
CTD
PMID:20103597
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
G
Cdh1
cadherin 1
increases expression
ISO
Gemcitabine results in increased expression of CDH1 mRNA
CTD
PMID:17039268
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
G
Cdkn1a
cyclin-dependent kinase inhibitor 1A
increases expression multiple interactions
ISO
Gemcitabine results in increased expression of CDKN1A mRNA; Gemcitabine results in increased expression of CDKN1A protein [alvocidib co-treated with Gemcitabine] results in increased expression of CDKN1A protein; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of CDKN1A protein; Nicotine inhibits the reaction [Gemcitabine results in increased expression of CDKN1A protein]
CTD
PMID:15476743 PMID:15770523 PMID:16601104 PMID:17039268 PMID:25189999
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
G
Cdkn1b
cyclin-dependent kinase inhibitor 1B
decreases response to substance
ISO
CDKN1B results in decreased susceptibility to Gemcitabine
CTD
PMID:21652059
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
G
Cebpb
CCAAT/enhancer binding protein beta
increases expression
ISO
Gemcitabine results in increased expression of CEBPB mRNA
CTD
PMID:17039268
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
G
Chrdl2
chordin-like 2
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CHRDL2 protein
CTD
PMID:24979617
NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640
G
Ckb
creatine kinase B
decreases expression
ISO
Gemcitabine results in decreased expression of CKB mRNA
CTD
PMID:17039268
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
G
Clic4
chloride intracellular channel 4
increases expression
ISO
Gemcitabine results in increased expression of CLIC4 mRNA
CTD
PMID:17039268
NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452
G
Clu
clusterin
increases expression affects response to substance
ISO
Gemcitabine results in increased expression of CLU protein CLU protein affects the susceptibility to Gemcitabine
CTD
PMID:19007378
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
G
Cnr1
cannabinoid receptor 1
multiple interactions increases expression
ISO
BAY 11-7085 inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]; Dactinomycin inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]
CTD
PMID:21525939
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
G
Cnr2
cannabinoid receptor 2
multiple interactions increases expression
ISO
BAY 11-7085 inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]; Dactinomycin inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]
CTD
PMID:21525939
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
G
Col1a1
collagen type I alpha 1 chain
decreases expression multiple interactions
ISO
Gemcitabine results in decreased expression of COL1A1 protein Gemcitabine inhibits the reaction [Niclosamide results in decreased expression of COL1A1 protein]; Niclosamide inhibits the reaction [Gemcitabine results in decreased expression of COL1A1 protein]
CTD
PMID:35115509
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
G
Csf2
colony stimulating factor 2
decreases expression
ISO
Gemcitabine results in decreased expression of CSF2 protein
CTD
PMID:20531411
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
G
Csf3
colony stimulating factor 3
decreases expression
ISO
Gemcitabine results in decreased expression of CSF3 protein
CTD
PMID:20531411
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
G
Csrp2
cysteine and glycine-rich protein 2
increases expression
ISO
Gemcitabine results in increased expression of CSRP2 mRNA
CTD
PMID:17039268
NCBI chr 7:46,349,109...46,367,743
Ensembl chr 7:46,348,686...46,367,745
G
Cthrc1
collagen triple helix repeat containing 1
increases expression
ISO
Gemcitabine results in increased expression of CTHRC1 mRNA
CTD
PMID:17039268
NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756
G
Ctnnb1
catenin beta 1
increases expression decreases expression
ISO
Gemcitabine results in increased expression of CTNNB1 mRNA Gemcitabine results in decreased expression of CTNNB1 protein
CTD
PMID:25605917 PMID:38000456
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
G
Cxcl1
C-X-C motif chemokine ligand 1
increases expression
ISO
Gemcitabine results in increased expression of CXCL1 mRNA
CTD
PMID:17039268
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
G
Cxcl11
C-X-C motif chemokine ligand 11
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CXCL11 protein
CTD
PMID:24979617
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
G
Cxcl2
C-X-C motif chemokine ligand 2
increases expression
ISO
Gemcitabine results in increased expression of CXCL2 mRNA
CTD
PMID:17039268
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
G
Cxcl3
C-X-C motif chemokine ligand 3
increases expression
ISO
Gemcitabine results in increased expression of CXCL1 mRNA
CTD
PMID:17039268
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
G
Cxcr4
C-X-C motif chemokine receptor 4
affects expression
ISO
Gemcitabine affects the expression of CXCR4 mRNA
CTD
PMID:20103597
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
G
Cyp24a1
cytochrome P450, family 24, subfamily a, polypeptide 1
decreases expression
ISO
Gemcitabine results in decreased expression of CYP24A1 mRNA
CTD
PMID:17039268
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
G
Ddit4
DNA-damage-inducible transcript 4
affects expression
ISO
Gemcitabine affects the expression of DDIT4 mRNA
CTD
PMID:17039268
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
G
Dhx9
DExH-box helicase 9
decreases expression
ISO
Gemcitabine results in decreased expression of DHX9 mRNA
CTD
PMID:17039268
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
G
Dlg2
discs large MAGUK scaffold protein 2
increases expression
ISO
Gemcitabine results in increased expression of DLG2 mRNA
CTD
PMID:17039268
NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475
G
Dnmt1
DNA methyltransferase 1
multiple interactions
ISO
[DNMT1 protein binds to SFN promoter] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; [Gemcitabine results in decreased susceptibility to Gemcitabine] inhibits the reaction [DNMT1 protein binds to SFN promoter]; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of DNMT1 protein; [UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; DNMT1 protein inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]
CTD
PMID:25189999
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
G
Dnmt3b
DNA methyltransferase 3 beta
multiple interactions
ISO
[Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of DNMT3B protein
CTD
PMID:25189999
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
G
Dpyd
dihydropyrimidine dehydrogenase
multiple interactions
ISO
[TYMP protein co-treated with DPYD protein] affects the susceptibility to Gemcitabine
CTD
PMID:18728667
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
G
Dync1h1
dynein cytoplasmic 1 heavy chain 1
decreases expression
ISO
Gemcitabine results in decreased expression of DYNC1H1 mRNA
CTD
PMID:17039268
NCBI chr 6:129,615,208...129,680,888
Ensembl chr 6:129,609,397...129,680,883
G
Edn1
endothelin 1
decreases expression
ISO
Gemcitabine results in decreased expression of EDN1 protein
CTD
PMID:20531411
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
G
Edn2
endothelin 2
decreases expression
ISO
Gemcitabine results in decreased expression of EDN2 mRNA
CTD
PMID:17039268
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
G
Egf
epidermal growth factor
multiple interactions decreases expression
ISO
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; U 0126 inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]] Gemcitabine results in decreased expression of EGF protein
CTD
PMID:20531411 PMID:21613822
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
G
Egfr
epidermal growth factor receptor
multiple interactions decreases expression increases expression increases phosphorylation increases degradation
ISO
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; EGFR gene mutant form results in increased susceptibility to [Gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Gefitinib inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gemcitabine promotes the reaction [HER3 protein binds to EGFR protein] Gemcitabine results in decreased expression of EGFR mRNA; Gemcitabine results in decreased expression of EGFR protein Gemcitabine results in increased expression of EGFR mRNA Gemcitabine results in increased phosphorylation of EGFR protein Gemcitabine results in increased degradation of EGFR protein
CTD
PMID:17146438 PMID:20103597 PMID:20726858 PMID:21541241
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
G
Egr1
early growth response 1
increases expression
ISO
Gemcitabine results in increased expression of EGR1 mRNA
CTD
PMID:17039268
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
G
Esr1
estrogen receptor 1
multiple interactions
ISO
Gemcitabine binds to and results in decreased activity of ESR1 protein
CTD
PMID:25752796
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Etv1
ETS variant transcription factor 1
increases expression
ISO
Gemcitabine results in increased expression of ETV1 mRNA
CTD
PMID:17039268
NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775
G
Evi2b
ecotropic viral integration site 2B
decreases expression
ISO
Gemcitabine results in decreased expression of EVI2B mRNA
CTD
PMID:17039268
NCBI chr10:64,472,693...64,474,311
Ensembl chr10:64,471,505...64,481,560
G
F7
coagulation factor VII
decreases expression
ISO
Gemcitabine results in decreased expression of F7 protein
CTD
PMID:20531411
NCBI chr16:76,489,775...76,500,636
Ensembl chr16:76,489,717...76,500,610
G
Fas
Fas cell surface death receptor
increases expression
ISO
Gemcitabine results in increased expression of FAS mRNA; Gemcitabine results in increased expression of FAS protein
CTD
PMID:11138460 PMID:17159604
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
G
Fbxo25
F-box protein 25
increases expression
ISO
Gemcitabine results in increased expression of FBXO25 mRNA
CTD
PMID:17039268
NCBI chr16:75,666,062...75,701,770
Ensembl chr16:75,667,904...75,701,696
G
Fgf2
fibroblast growth factor 2
increases expression multiple interactions
ISO
Gemcitabine results in increased expression of FGF2 protein [Gemcitabine co-treated with IFNA2 protein] results in increased expression of FGF2 protein
CTD
PMID:12738744 PMID:20531411
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
G
Fgg
fibrinogen gamma chain
affects expression
ISO
Gemcitabine affects the expression of FGG mRNA
CTD
PMID:17039268
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
G
Fosl2
FOS like 2, AP-1 transcription factor subunit
decreases expression
ISO
Gemcitabine results in decreased expression of FOSL2 mRNA
CTD
PMID:17039268
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
G
Fxyd3
FXYD domain-containing ion transport regulator 3
increases expression
ISO
Gemcitabine results in increased expression of FXYD3 mRNA
CTD
PMID:17039268
NCBI chr 1:86,305,531...86,312,455
G
Gal3st1
galactose-3-O-sulfotransferase 1
decreases expression
ISO
Gemcitabine results in decreased expression of GAL3ST1 mRNA
CTD
PMID:17039268
NCBI chr14:78,868,049...78,886,402
Ensembl chr14:78,870,793...78,886,388
G
Gas1
growth arrest-specific 1
decreases expression
ISO
Gemcitabine results in decreased expression of GAS1 mRNA
CTD
PMID:17039268
NCBI chr17:4,482,168...4,485,153
G
Gask1b
golgi associated kinase 1B
decreases expression
ISO
Gemcitabine results in decreased expression of GASK1B mRNA
CTD
PMID:17039268
NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477
G
Gdf15
growth differentiation factor 15
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of GDF15 protein
CTD
PMID:24979617
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
G
Gipc1
GIPC PDZ domain containing family, member 1
affects response to substance
ISO
GIPC1 affects the susceptibility to Gemcitabine
CTD
PMID:25469510
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
G
Gli2
GLI family zinc finger 2
affects expression
ISO
Gemcitabine affects the expression of GLI2 mRNA
CTD
PMID:20103597
NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574
G
Glrx
glutaredoxin
increases expression
ISO
Gemcitabine results in increased expression of GLRX mRNA
CTD
PMID:17039268
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
G
Gpc3
glypican 3
increases expression
ISO
Gemcitabine results in increased expression of GPC3 mRNA
CTD
PMID:17039268
NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798
G
Gsk3b
glycogen synthase kinase 3 beta
increases phosphorylation
ISO
Gemcitabine results in increased phosphorylation of GSK3B protein
CTD
PMID:16570353
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
G
Gtf2a1
general transcription factor 2A subunit 1
affects expression
ISO
Gemcitabine affects the expression of GTF2A1 mRNA
CTD
PMID:17039268
NCBI chr 6:110,488,891...110,521,502
Ensembl chr 6:110,488,931...110,521,511
G
H2ax
H2A.X variant histone
increases expression multiple interactions
ISO
Gemcitabine results in increased expression of H2AX protein; Gemcitabine results in increased expression of H2AX protein modified form PIF1 protein inhibits the reaction [Gemcitabine results in increased expression of H2AX protein]; Thymidine inhibits the reaction [PIF1 protein inhibits the reaction [Gemcitabine results in increased expression of H2AX protein]]
CTD
PMID:20798217 PMID:37183367 PMID:38000456
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
G
H4c14
H4 clustered histone 14
decreases expression
ISO
Gemcitabine results in decreased expression of H4C2 mRNA
CTD
PMID:17039268
NCBI chr 2:183,831,601...183,831,996
Ensembl chr 2:183,825,994...183,832,048
G
Hdac9
histone deacetylase 9
increases expression
ISO
Gemcitabine results in increased expression of HDAC9 mRNA
CTD
PMID:17039268
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
G
Hif1a
hypoxia inducible factor 1 subunit alpha
affects response to substance
ISO
HIF1A protein affects the susceptibility to Gemcitabine
CTD
PMID:16628086
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
G
Hmox1
heme oxygenase 1
multiple interactions increases expression
ISO
CASC9 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 mRNA]; CASC9 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 mRNA] Gemcitabine results in increased expression of HMOX1 mRNA; Gemcitabine results in increased expression of HMOX1 protein
CTD
PMID:35913601
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
G
Hoxb2
homeobox B2
increases expression
ISO
Gemcitabine results in increased expression of HOXB2 mRNA
CTD
PMID:17039268
NCBI chr10:81,317,828...81,320,220
Ensembl chr10:81,318,026...81,320,192
G
Hspa1l
heat shock protein family A (Hsp70) member 1 like
decreases expression
ISO
Gemcitabine results in decreased expression of HSPA1L mRNA
CTD
PMID:17039268
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
G
Hspa5
heat shock protein family A (Hsp70) member 5
increases expression
ISO
Gemcitabine results in increased expression of HSPA5 mRNA
CTD
PMID:17039268
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
G
Icam1
intercellular adhesion molecule 1
decreases expression multiple interactions
ISO
Gemcitabine results in decreased expression of ICAM1 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of ICAM1 protein
CTD
PMID:17440100 PMID:20531411
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
G
Ifng
interferon gamma
decreases expression
ISO
Gemcitabine results in decreased expression of IFNG protein
CTD
PMID:20531411
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
G
Igf1r
insulin-like growth factor 1 receptor
decreases expression
ISO
Gemcitabine results in decreased expression of IGF1R mRNA
CTD
PMID:20103597
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
G
Igfbp3
insulin-like growth factor binding protein 3
affects expression
ISO
Gemcitabine affects the expression of IGFBP3 mRNA
CTD
PMID:20103597
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
G
Il10
interleukin 10
decreases expression
ISO
Gemcitabine results in decreased expression of IL10 protein
CTD
PMID:20531411
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
G
Il13
interleukin 13
increases expression
ISO
Gemcitabine results in increased expression of IL13 protein
CTD
PMID:20531411
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
G
Il15
interleukin 15
decreases expression
ISO
Gemcitabine results in decreased expression of IL15 protein
CTD
PMID:20531411
NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820
G
Il16
interleukin 16
increases expression
ISO
Gemcitabine results in increased expression of IL16 protein
CTD
PMID:20531411
NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130
G
Il1a
interleukin 1 alpha
decreases expression
ISO
Gemcitabine results in decreased expression of IL1A protein
CTD
PMID:20531411
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
G
Il1b
interleukin 1 beta
decreases expression multiple interactions
ISO
Gemcitabine results in decreased expression of IL1B protein [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 protein]
CTD
PMID:20531411 PMID:32894642
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il4
interleukin 4
decreases expression
ISO
Gemcitabine results in decreased expression of IL4 protein
CTD
PMID:20531411
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
G
Il6
interleukin 6
increases secretion increases expression decreases expression
ISO
Gemcitabine results in increased secretion of IL6 protein Gemcitabine results in increased expression of IL6 mRNA Gemcitabine results in decreased expression of IL6 protein
CTD
PMID:17039268 PMID:20531411 PMID:28007550
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Ilk
integrin-linked kinase
affects response to substance
ISO
ILK protein affects the susceptibility to Gemcitabine
CTD
PMID:15867245
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
G
Ins2
insulin 2
increases expression
ISO
Gemcitabine results in increased expression of INS protein
CTD
PMID:20531411
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
G
Insig1
insulin induced gene 1
increases expression
ISO
Gemcitabine results in increased expression of INSIG1 mRNA
CTD
PMID:17039268
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
G
Iqgap1
IQ motif containing GTPase activating protein 1
increases expression
ISO
Gemcitabine results in increased expression of IQGAP1 mRNA
CTD
PMID:17039268
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
G
Irak2
interleukin-1 receptor-associated kinase 2
increases expression
ISO
Gemcitabine results in increased expression of IRAK2 mRNA
CTD
PMID:17039268
NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602
G
Irf3
interferon regulatory factor 3
decreases expression
ISO
Gemcitabine results in decreased expression of IRF3 mRNA
CTD
PMID:17039268
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
G
Itgav
integrin subunit alpha V
multiple interactions
ISO
[ITGB6 co-treated with ITGAV] affects the susceptibility to Gemcitabine
CTD
PMID:20150628
NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
G
Itgb6
integrin subunit beta 6
multiple interactions
ISO
[ITGB6 co-treated with ITGAV] affects the susceptibility to Gemcitabine
CTD
PMID:20150628
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
G
Itsn2
intersectin 2
increases expression
ISO
Gemcitabine results in increased expression of ITSN2 mRNA
CTD
PMID:17039268
NCBI chr 6:27,616,645...27,727,373
Ensembl chr 6:27,600,406...27,727,124
G
Jam3
junctional adhesion molecule 3
decreases expression
ISO
Gemcitabine results in decreased expression of JAM3 mRNA
CTD
PMID:17039268
NCBI chr 8:25,508,461...25,569,306
Ensembl chr 8:25,507,057...25,569,355
G
Jun
Jun proto-oncogene, AP-1 transcription factor subunit
multiple interactions
ISO
[Copper co-treated with Disulfiram co-treated with Gemcitabine] results in increased expression of and results in increased phosphorylation of JUN protein
CTD
PMID:23033007
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
G
Kctd12
potassium channel tetramerization domain containing 12
decreases expression
ISO
Gemcitabine results in decreased expression of KCTD12 mRNA
CTD
PMID:17039268
NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
G
Kitlg
KIT ligand
multiple interactions decreases expression
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of KITLG protein Gemcitabine results in decreased expression of KITLG protein
CTD
PMID:20531411 PMID:24979617
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
G
Klf8
KLF transcription factor 8
increases expression
ISO
Gemcitabine results in increased expression of KLF8 mRNA
CTD
PMID:17039268
NCBI chr X:17,950,045...18,132,980
Ensembl chr X:17,958,843...18,133,182
G
Krt8
keratin 8
decreases expression
ISO
Gemcitabine results in decreased expression of KRT8 mRNA
CTD
PMID:17039268
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
G
Larp4b
La ribonucleoprotein 4B
increases expression
ISO
Gemcitabine results in increased expression of LARP4B mRNA
CTD
PMID:17039268
NCBI chr17:61,138,663...61,217,423
Ensembl chr17:61,138,709...61,187,960
G
Lep
leptin
decreases expression
ISO
Gemcitabine results in decreased expression of LEP protein
CTD
PMID:20531411
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
G
Lifr
LIF receptor subunit alpha
increases expression
ISO
Gemcitabine results in increased expression of LIFR mRNA
CTD
PMID:17039268
NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
G
Lpar6
lysophosphatidic acid receptor 6
decreases expression
ISO
Gemcitabine results in decreased expression of LPAR6 mRNA
CTD
PMID:17039268
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
G
Lrrc28
leucine rich repeat containing 28
increases expression
ISO
Gemcitabine results in increased expression of LRRC28 mRNA
CTD
PMID:17039268
NCBI chr 1:121,116,833...121,245,805
Ensembl chr 1:121,127,733...121,245,784
G
Lta
lymphotoxin alpha
increases expression
ISO
Gemcitabine results in increased expression of LTA protein
CTD
PMID:20531411
NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859
G
Lyz2
lysozyme 2
decreases expression
ISO
Gemcitabine results in decreased expression of LYZ mRNA
CTD
PMID:17039268
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
G
Maf
MAF bZIP transcription factor
increases expression
ISO
Gemcitabine results in increased expression of MAF mRNA
CTD
PMID:17039268
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
G
Magea10
MAGE family member A10
decreases expression
ISO
Gemcitabine results in decreased expression of MAGEA10 mRNA
CTD
PMID:17039268
NCBI chr X:150,212,708...150,217,954
Ensembl chr X:150,213,245...150,214,213
G
Magi1
membrane associated guanylate kinase, WW and PDZ domain containing 1
increases expression
ISO
Gemcitabine results in increased expression of MAGI1 mRNA
CTD
PMID:17039268
NCBI chr 4:126,205,663...126,811,354
Ensembl chr 4:126,206,816...126,811,691
G
Map2k3
mitogen activated protein kinase kinase 3
increases phosphorylation
ISO
Gemcitabine results in increased phosphorylation of MAP2K3 protein
CTD
PMID:15003513
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
G
Map2k6
mitogen-activated protein kinase kinase 6
increases phosphorylation
ISO
Gemcitabine results in increased phosphorylation of MAP2K6 protein
CTD
PMID:15003513
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
G
Mapk1
mitogen activated protein kinase 1
increases phosphorylation multiple interactions
ISO
Gemcitabine results in increased phosphorylation of MAPK1 protein [Copper co-treated with Disulfiram co-treated with Gemcitabine] results in increased phosphorylation of MAPK1 protein
CTD
PMID:15476743 PMID:23033007
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
G
Mapk3
mitogen activated protein kinase 3
increases phosphorylation multiple interactions
ISO
Gemcitabine results in increased phosphorylation of MAPK3 protein [Copper co-treated with Disulfiram co-treated with Gemcitabine] results in increased phosphorylation of MAPK3 protein
CTD
PMID:15476743 PMID:23033007
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
G
Marcks
myristoylated alanine rich protein kinase C substrate
increases expression increases phosphorylation
ISO
Gemcitabine results in increased expression of MARCKS mRNA Gemcitabine results in increased phosphorylation of MARCKS protein
CTD
PMID:9523737 PMID:17039268
NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012
G
Mars1
methionyl-tRNA synthetase 1
increases expression
ISO
Gemcitabine results in increased expression of MARS1 mRNA
CTD
PMID:17039268
NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495
G
Mdm2
MDM2 proto-oncogene
increases expression decreases expression
ISO
Gemcitabine results in increased expression of MDM2 mRNA Gemcitabine results in decreased expression of MDM2 mRNA
CTD
PMID:17039268 PMID:20103597
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
G
Mgmt
O-6-methylguanine-DNA methyltransferase
decreases expression
ISO
Gemcitabine results in decreased expression of MGMT mRNA
CTD
PMID:17039268
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
G
Mir222
microRNA 222
affects response to substance
ISO
MIR222 mRNA affects the susceptibility to Gemcitabine
CTD
PMID:35974258
NCBI chr X:3,428,904...3,429,006
Ensembl chr X:3,428,904...3,429,006
G
Mir24-2
microRNA 24-2
multiple interactions
ISO
MIR24-2 mRNA affects the susceptibility to [Betulinic Acid co-treated with Gemcitabine]
CTD
PMID:25841339
NCBI chr19:23,954,683...23,954,790
Ensembl chr19:23,954,683...23,954,790
G
Mki67
marker of proliferation Ki-67
multiple interactions decreases expression
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of MKI67 protein Gemcitabine results in decreased expression of MKI67 protein
CTD
PMID:17440100 PMID:38000456
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
G
Mmp3
matrix metallopeptidase 3
decreases expression
ISO
Gemcitabine results in decreased expression of MMP3 protein
CTD
PMID:20531411
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
G
Mmp9
matrix metallopeptidase 9
multiple interactions
ISO
[Gemcitabine co-treated with IFNA2 protein] results in increased expression of MMP9 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of MMP9 protein
CTD
PMID:12738744 PMID:17440100
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
G
Mpo
myeloperoxidase
increases expression
ISO
Gemcitabine results in increased expression of MPO protein
CTD
PMID:20531411
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
G
Msln
mesothelin
multiple interactions
EXP
Gemcitabine results in decreased expression of and results in decreased secretion of MSLN protein alternative form
CTD
PMID:25347530
NCBI chr10:14,771,946...14,781,382
Ensembl chr10:14,771,961...14,777,643
G
Mt-co3
mitochondrially encoded cytochrome c oxidase III
multiple interactions decreases response to substance
ISO
Sodium Azide inhibits the reaction [COX3 protein results in decreased susceptibility to Gemcitabine]
CTD
PMID:17428446
NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
G
Mxi1
MAX interactor 1, dimerization protein
increases expression
ISO
Gemcitabine results in increased expression of MXI1 mRNA
CTD
PMID:17039268
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
G
Myb
MYB proto-oncogene, transcription factor
increases expression
ISO
Gemcitabine results in increased expression of MYB mRNA
CTD
PMID:17039268
NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
G
Myc
MYC proto-oncogene, bHLH transcription factor
multiple interactions affects response to substance
ISO
[Oligonucleotides binds to MYC gene] which results in increased susceptibility to Gemcitabine [Curcumin co-treated with Gemcitabine] results in decreased expression of MYC protein MYC affects the susceptibility to Gemcitabine
CTD
PMID:17440100 PMID:23681918
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
G
Nanog
Nanog homeobox
decreases expression
ISO
Gemcitabine results in decreased expression of NANOG mRNA
CTD
PMID:25605917 PMID:35063459
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
G
Ncbp1
nuclear cap binding protein subunit 1
increases expression
ISO
Gemcitabine results in increased expression of NCBP1 mRNA
CTD
PMID:17039268
NCBI chr 5:60,416,023...60,449,004
Ensembl chr 5:60,415,982...60,449,089
G
Nedd9
neural precursor cell expressed, developmentally down-regulated 9
increases expression
ISO
Gemcitabine results in increased expression of NEDD9 mRNA
CTD
PMID:17039268
NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019
G
Neu1
neuraminidase 1
increases expression
ISO
Gemcitabine results in increased expression of NEU1 mRNA
CTD
PMID:17039268
NCBI chr20:3,897,480...3,901,745
Ensembl chr20:3,897,480...3,901,745
G
Nfe2l2
NFE2 like bZIP transcription factor 2
decreases response to substance increases expression multiple interactions
ISO
NFE2L2 protein results in decreased susceptibility to Gemcitabine Gemcitabine results in increased expression of NFE2L2 mRNA; Gemcitabine results in increased expression of NFE2L2 protein CASC9 protein affects the reaction [Gemcitabine results in increased expression of NFE2L2 mRNA]; CASC9 protein affects the reaction [Gemcitabine results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of CASC9 mRNA]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of NQO1 mRNA]
CTD
PMID:21489257 PMID:35913601
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
G
Nfkb2
nuclear factor kappa B subunit 2
affects expression
ISO
Gemcitabine affects the expression of NFKB2 mRNA
CTD
PMID:17039268
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
G
Nfkbia
NFKB inhibitor alpha
multiple interactions
ISO
[Mastic Resin co-treated with Gemcitabine] results in increased expression of NFKBIA protein
CTD
PMID:20523344
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
G
Nfkbie
NFKB inhibitor epsilon
affects expression
ISO
Gemcitabine affects the expression of NFKBIE mRNA
CTD
PMID:17039268
NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437
G
Nnmt
nicotinamide N-methyltransferase
increases expression
ISO
Gemcitabine results in increased expression of NNMT mRNA
CTD
PMID:17039268
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
G
Notch1
notch receptor 1
multiple interactions increases expression
ISO
sulforaphane inhibits the reaction [Gemcitabine results in increased expression of NOTCH1 protein]
CTD
PMID:20940707
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
G
Npepps
aminopeptidase puromycin sensitive
decreases expression
ISO
Gemcitabine results in decreased expression of NPEPPS mRNA
CTD
PMID:17039268
NCBI chr10:82,191,454...82,273,967
Ensembl chr10:82,191,456...82,273,967
G
Npm1
nucleophosmin 1
decreases response to substance
ISO
NPM1 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:24736981
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
G
Nqo1
NAD(P)H quinone dehydrogenase 1
multiple interactions increases expression
ISO
CASC9 protein affects the reaction [Gemcitabine results in increased expression of NQO1 mRNA]; CASC9 protein affects the reaction [Gemcitabine results in increased expression of NQO1 protein]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of NQO1 mRNA] Gemcitabine results in increased expression of NQO1 mRNA; Gemcitabine results in increased expression of NQO1 protein
CTD
PMID:35913601
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
G
Nr4a3
nuclear receptor subfamily 4, group A, member 3
increases expression
ISO
Gemcitabine results in increased expression of NR4A3 mRNA
CTD
PMID:17039268
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
G
Nrg1
neuregulin 1
increases expression
ISO
Gemcitabine results in increased expression of NRG1 mRNA
CTD
PMID:17039268
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
G
Nrp1
neuropilin 1
decreases response to substance
ISO
NRP1 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:15956974
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
G
Nupr1
nuclear protein 1, transcriptional regulator
decreases expression affects response to substance
ISO
Gemcitabine results in decreased expression of NUPR1 mRNA NUPR1 affects the susceptibility to Gemcitabine
CTD
PMID:16397047
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
G
Or4d6
olfactory receptor family 4 subfamily D member 6
affects response to substance
ISO
OR4D6 gene SNP affects the susceptibility to Gemcitabine
CTD
PMID:26378035
NCBI chr 1:209,039,073...209,040,017
Ensembl chr 1:209,037,992...209,045,985
G
Osm
oncostatin M
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of OSM protein
CTD
PMID:24979617
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
G
Pappa
pappalysin
decreases expression
ISO
Gemcitabine results in decreased expression of PAPPA protein
CTD
PMID:20531411
NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:78,498,300...78,730,666
G
Paqr8
progestin and adipoQ receptor family member 8
increases expression
ISO
Gemcitabine results in increased expression of PAQR8 mRNA
CTD
PMID:17039268
NCBI chr 9:23,312,521...23,362,175
Ensembl chr 9:23,312,585...23,362,340
G
Parp1
poly (ADP-ribose) polymerase 1
increases cleavage multiple interactions
ISO
Gemcitabine results in increased cleavage of PARP1 protein [alvocidib co-treated with Gemcitabine] results in increased cleavage of PARP1 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; SFN protein inhibits the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; YAP1 protein affects the reaction [Gemcitabine results in increased cleavage of PARP1 protein]
CTD
PMID:15770523 PMID:17146438 PMID:26894857
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
G
Parp2
poly (ADP-ribose) polymerase 2
decreases response to substance
ISO
PARP2 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:20798217
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
G
Pcsk9
proprotein convertase subtilisin/kexin type 9
increases expression
ISO
Gemcitabine results in increased expression of PCSK9 mRNA
CTD
PMID:17039268
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
G
Pdpk1
3-phosphoinositide dependent protein kinase-1
decreases response to substance
ISO
PDPK1 protein modified form results in decreased susceptibility to Gemcitabine
CTD
PMID:16782806
NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623
G
Pdzk1ip1
PDZK1 interacting protein 1
increases expression
ISO
Gemcitabine results in increased expression of PDZK1IP1 mRNA
CTD
PMID:17039268
NCBI chr 5:128,618,050...128,623,131
Ensembl chr 5:128,618,237...128,623,131
G
Pecam1
platelet and endothelial cell adhesion molecule 1
multiple interactions
ISO
Gemcitabine promotes the reaction [Curcumin results in decreased expression of PECAM1 protein]
CTD
PMID:17440100
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
G
Pgr
progesterone receptor
multiple interactions
ISO
Gemcitabine binds to and results in decreased activity of PGR protein
CTD
PMID:25752796
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Pif1
PIF1 5'-to-3' DNA helicase
decreases response to substance affects response to substance multiple interactions
ISO
PIF1 protein results in decreased susceptibility to Gemcitabine PIF1 protein affects the susceptibility to Gemcitabine PIF1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP3 protein]; PIF1 protein inhibits the reaction [Gemcitabine results in increased expression of H2AX protein]; Thymidine inhibits the reaction [PIF1 protein inhibits the reaction [Gemcitabine results in increased expression of H2AX protein]]
CTD
PMID:37183367
NCBI chr 8:66,110,641...66,120,202
Ensembl chr 8:66,111,072...66,120,200
G
Pja2
praja ring finger ubiquitin ligase 2
increases expression
ISO
Gemcitabine results in increased expression of PJA2 mRNA
CTD
PMID:17039268
NCBI chr 9:103,956,678...104,006,763
Ensembl chr 9:103,956,678...104,006,783
G
Pkm
pyruvate kinase M1/2
affects response to substance
ISO
PKM protein alternative form affects the susceptibility to Gemcitabine
CTD
PMID:38000456
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
G
Plau
plasminogen activator, urokinase
increases expression
ISO
Gemcitabine results in increased expression of PLAU mRNA
CTD
PMID:17039268
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
G
Plk1
polo-like kinase 1
decreases expression multiple interactions affects response to substance
ISO
Gemcitabine results in decreased expression of PLK1; Gemcitabine results in decreased expression of PLK1 mRNA [Gemcitabine results in decreased expression of PLK1] which results in increased susceptibility to Gemcitabine; ON 01910 promotes the reaction [PLK1 protein affects the susceptibility to Gemcitabine]
CTD
PMID:20103597
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
G
Pou5f1
POU class 5 homeobox 1
decreases expression
ISO
Gemcitabine results in decreased expression of POU5F1 mRNA
CTD
PMID:35063459
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
G
Ppara
peroxisome proliferator activated receptor alpha
affects expression
ISO
Gemcitabine affects the expression of PPARA mRNA
CTD
PMID:19427843
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
G
Ppard
peroxisome proliferator-activated receptor delta
affects expression
ISO
Gemcitabine affects the expression of PPARD mRNA
CTD
PMID:19427843
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
G
Pparg
peroxisome proliferator-activated receptor gamma
affects expression
ISO
Gemcitabine affects the expression of PPARG mRNA
CTD
PMID:19427843
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
G
Ppfia4
PTPRF interacting protein alpha 4
increases expression
ISO
Gemcitabine results in increased expression of PPFIA4 mRNA
CTD
PMID:17039268
NCBI chr13:45,753,827...45,802,305
Ensembl chr13:45,753,827...45,802,261
G
Ppp1r15a
protein phosphatase 1, regulatory subunit 15A
increases expression
ISO
Gemcitabine results in increased expression of PPP1R15A mRNA
CTD
PMID:17039268
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
G
Psat1
phosphoserine aminotransferase 1
increases expression
ISO
Gemcitabine results in increased expression of PSAT1 mRNA
CTD
PMID:17039268
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
G
Ptch1
patched 1
affects expression
ISO
Gemcitabine affects the expression of PTCH1 mRNA
CTD
PMID:20103597
NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
G
Pten
phosphatase and tensin homolog
affects expression
ISO
Gemcitabine affects the expression of PTEN mRNA
CTD
PMID:17039268
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
G
Ptgs1
prostaglandin-endoperoxide synthase 1
decreases expression
ISO
Gemcitabine results in decreased expression of PTGS1 mRNA
CTD
PMID:17039268
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
G
Ptgs2
prostaglandin-endoperoxide synthase 2
multiple interactions
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of PTGS2 protein
CTD
PMID:17440100
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Ptk2
protein tyrosine kinase 2
decreases response to substance
ISO
PTK2 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:14623342
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
G
Ptpn11
protein tyrosine phosphatase, non-receptor type 11
affects expression
ISO
Gemcitabine affects the expression of PTPN11 mRNA
CTD
PMID:17039268
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
G
Rab8a
RAB8A, member RAS oncogene family
decreases expression
ISO
Gemcitabine results in decreased expression of RAB8A mRNA
CTD
PMID:17039268
NCBI chr16:17,654,027...17,675,385
Ensembl chr16:17,654,034...17,675,678
G
Rbm17
RNA binding motif protein 17
decreases response to substance
ISO
RBM17 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:16061639
NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014
G
Reg3b
regenerating family member 3 beta
decreases expression
ISO
Gemcitabine results in decreased expression of REG3A mRNA
CTD
PMID:16570353
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
G
Rel
REL proto-oncogene, NF-kB subunit
multiple interactions decreases expression
ISO
sulforaphane promotes the reaction [Gemcitabine results in decreased expression of REL protein]
CTD
PMID:20940707
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
G
Rela
RELA proto-oncogene, NF-kB subunit
increases phosphorylation increases expression multiple interactions
ISO
Gemcitabine results in increased phosphorylation of RELA protein Gemcitabine results in increased expression of RELA protein [Curcumin co-treated with Gemcitabine] results in decreased expression of RELA protein [Gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] affects the localization of RELA protein; [Gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] results in increased expression of RELA protein; licoricidin inhibits the reaction [Gemcitabine results in increased phosphorylation of RELA protein]; Mastic Resin inhibits the reaction [Gemcitabine results in increased expression of RELA protein]
CTD
PMID:17039268 PMID:17440100 PMID:20523344 PMID:29782821
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Rgs2
regulator of G-protein signaling 2
increases expression
ISO
Gemcitabine results in increased expression of RGS2 mRNA
CTD
PMID:17039268
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
G
Rnf149
ring finger protein 149
increases expression
ISO
Gemcitabine results in increased expression of RNF149 mRNA
CTD
PMID:17039268
NCBI chr 9:41,826,825...41,854,381
Ensembl chr 9:41,830,233...41,854,279
G
Rpl37
ribosomal protein L37
increases expression
ISO
Gemcitabine results in increased expression of RPL37 mRNA
CTD
PMID:17039268
NCBI chr 2:54,215,469...54,217,429
Ensembl chr 2:54,215,469...54,217,442
G
Rragd
Ras-related GTP binding D
increases expression
ISO
Gemcitabine results in increased expression of RRAGD mRNA
CTD
PMID:17039268
NCBI chr 5:47,373,902...47,409,369
Ensembl chr 5:47,373,463...47,409,356
G
Rrm1
ribonucleotide reductase catalytic subunit M1
affects response to substance multiple interactions
ISO
RRM1 protein affects the susceptibility to Gemcitabine [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of RRM1 mRNA; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of RRM1 protein
CTD
PMID:25189999 PMID:26894857
NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261
G
Rrm2
ribonucleotide reductase regulatory subunit M2
multiple interactions affects response to substance
ISO
[Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of RRM2 protein RRM2 protein affects the susceptibility to Gemcitabine
CTD
PMID:25189999 PMID:26894857
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
G
Rsl24d1
ribosomal L24 domain containing 1
increases expression
ISO
Gemcitabine results in increased expression of RSL24D1 mRNA
CTD
PMID:17039268
NCBI chr 8:73,852,991...73,861,996
Ensembl chr 8:73,852,996...73,862,001
G
Sat1
spermidine/spermine N1-acetyl transferase 1
increases expression
ISO
Gemcitabine results in increased expression of SAT1 mRNA
CTD
PMID:17039268
NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813
G
Scd
stearoyl-CoA desaturase
increases expression
ISO
Gemcitabine results in increased expression of SCD mRNA
CTD
PMID:17039268
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
G
Sfn
stratifin
affects response to substance multiple interactions increases methylation decreases response to substance
ISO
SFN protein affects the susceptibility to Gemcitabine [DNMT1 protein binds to SFN promoter] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; [Gemcitabine results in decreased susceptibility to Gemcitabine] inhibits the reaction [DNMT1 protein binds to SFN promoter]; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in decreased methylation of SFN gene; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of SFN mRNA; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of SFN protein; [UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; SFN protein affects the reaction [YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine]]; SFN protein inhibits the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]; SFN protein inhibits the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; SFN protein promotes the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine] Gemcitabine results in increased methylation of SFN gene
CTD
PMID:25189999 PMID:26894857
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
G
Shh
sonic hedgehog signaling molecule
decreases expression
ISO
Gemcitabine results in decreased expression of SHH mRNA
CTD
PMID:20103597
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
G
Slc25a29
solute carrier family 25 member 29
increases expression
ISO
Gemcitabine results in increased expression of SLC25A29 mRNA
CTD
PMID:17039268
NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940
G
Slc28a1
solute carrier family 28 member 1
multiple interactions
EXP ISO
Gemcitabine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] Gemcitabine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine]
CTD
PMID:8713072 PMID:10772724
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
G
Slc29a1
solute carrier family 29 member 1
affects response to substance increases uptake multiple interactions decreases response to substance increases response to substance
ISO
SLC29A1 protein affects the susceptibility to Gemcitabine SLC29A1 protein results in increased uptake of Gemcitabine 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Gemcitabine]; [S 1 (combination) results in increased expression of SLC29A1 mRNA] which results in increased uptake of Gemcitabine; Fluorouracil promotes the reaction [SLC29A1 protein results in increased uptake of Gemcitabine] SLC29A1 protein results in decreased susceptibility to Gemcitabine SLC29A1 mRNA results in increased susceptibility to Gemcitabine; SLC29A1 protein results in increased susceptibility to Gemcitabine
CTD
PMID:15501974 PMID:16868479 PMID:17695509 PMID:18383843 PMID:18452103 PMID:18490900 PMID:18728667 PMID:18992248 PMID:26894857 More...
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
G
Slc29a3
solute carrier family 29 member 3
affects transport
ISO
SLC29A3 protein affects the transport of Gemcitabine
CTD
PMID:19164483
NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388
G
Slc2a3
solute carrier family 2 member 3
increases expression
ISO
Gemcitabine results in increased expression of SLC2A3 mRNA
CTD
PMID:17039268
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
G
Slc43a3
solute carrier family 43, member 3
decreases expression
ISO
Gemcitabine results in decreased expression of SLC43A3 mRNA
CTD
PMID:17039268
NCBI chr 3:70,008,160...70,030,324
Ensembl chr 3:70,009,313...70,029,749
G
Slitrk2
SLIT and NTRK-like family, member 2
increases expression
ISO
Gemcitabine results in increased expression of SLITRK2 mRNA
CTD
PMID:17039268
NCBI chr X:145,246,448...145,259,983
Ensembl chr X:145,246,460...145,271,220
G
Smg1
SMG1, nonsense mediated mRNA decay associated PI3K related kinase
decreases response to substance multiple interactions
ISO
SMG1 protein results in decreased susceptibility to Gemcitabine SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP3 protein]; SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP9 protein]
CTD
PMID:21418860
NCBI chr 1:172,441,892...172,543,667
Ensembl chr 1:172,444,936...172,543,698
G
Smo
smoothened, frizzled class receptor
increases expression
ISO
Gemcitabine results in increased expression of SMO mRNA
CTD
PMID:25605917
NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829
G
Sox2
SRY-box transcription factor 2
increases expression
ISO
Gemcitabine results in increased expression of SOX2 mRNA
CTD
PMID:25605917
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
G
Spp1
secreted phosphoprotein 1
increases expression
ISO
Gemcitabine results in increased expression of SPP1 mRNA
CTD
PMID:17039268
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
G
Src
SRC proto-oncogene, non-receptor tyrosine kinase
affects response to substance decreases response to substance multiple interactions
ISO
SRC protein affects the susceptibility to Gemcitabine SRC protein modified form results in decreased susceptibility to Gemcitabine; SRC protein results in decreased susceptibility to Gemcitabine [AG 1879 co-treated with SRC] results in increased susceptibility to Gemcitabine
CTD
PMID:15073106 PMID:15194078
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
G
Stat3
signal transducer and activator of transcription 3
decreases activity
ISO
Gemcitabine results in decreased activity of STAT3 protein
CTD
PMID:22348037
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
G
Syncrip
synaptotagmin binding, cytoplasmic RNA interacting protein
decreases expression
ISO
Gemcitabine results in decreased expression of SYNCRIP mRNA
CTD
PMID:17039268
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
G
Szrd1
SUZ RNA binding domain containing 1
decreases expression
ISO
Gemcitabine results in decreased expression of SZRD1 mRNA
CTD
PMID:17039268
NCBI chr 5:153,418,748...153,443,286
Ensembl chr 5:153,418,748...153,443,252
G
Tceal9
transcription elongation factor A like 9
increases expression
ISO
Gemcitabine results in increased expression of TCEAL9 mRNA
CTD
PMID:17039268
NCBI chr X:99,245,645...99,247,720
Ensembl chr X:99,228,458...99,247,763
G
Tcof1
treacle ribosome biogenesis factor 1
decreases expression
ISO
Gemcitabine results in decreased expression of TCOF1 mRNA
CTD
PMID:17039268
NCBI chr18:54,267,015...54,300,324
Ensembl chr18:54,267,026...54,300,324
G
Tert
telomerase reverse transcriptase
multiple interactions decreases activity
ISO
[Fluorouracil co-treated with Gemcitabine] results in decreased activity of TERT protein Gemcitabine results in decreased activity of TERT protein
CTD
PMID:16929163
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
G
Tfap2a
transcription factor AP-2 alpha
increases response to substance multiple interactions
ISO
TFAP2A protein results in increased susceptibility to Gemcitabine [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Gemcitabine
CTD
PMID:21489314
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
G
Tgfb1
transforming growth factor, beta 1
multiple interactions decreases response to substance
ISO
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; U 0126 inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]
CTD
PMID:21613822
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
G
Tgfb2
transforming growth factor, beta 2
increases expression
ISO
Gemcitabine results in increased expression of TGFB2 mRNA
CTD
PMID:17039268
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
G
Thpo
thrombopoietin
increases expression
ISO
Gemcitabine results in increased expression of THPO protein
CTD
PMID:20531411
Ensembl chr11:80,182,820...80,188,167
G
Tnf
tumor necrosis factor
increases expression affects expression
ISO
Gemcitabine results in increased expression of TNF protein Gemcitabine affects the expression of TNF mRNA
CTD
PMID:17039268 PMID:20531411
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tnfaip3
TNF alpha induced protein 3
increases expression
ISO
Gemcitabine results in increased expression of TNFAIP3 mRNA
CTD
PMID:17039268
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
G
Tnfrsf11b
TNF receptor superfamily member 11B
increases expression
ISO
Gemcitabine results in increased expression of TNFRSF11B mRNA
CTD
PMID:17039268
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
G
Tnfsf10
TNF superfamily member 10
multiple interactions
ISO
[TNFSF10 co-treated with Gemcitabine] affects the localization of BAX protein; [TNFSF10 co-treated with Gemcitabine] results in increased activity of CASP8 protein
CTD
PMID:17671697
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
G
Tnfsf8
TNF superfamily member 8
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of TNFSF8 protein
CTD
PMID:24979617
NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421
G
Tp53
tumor protein p53
increases expression multiple interactions affects activity
ISO
Gemcitabine results in increased expression of TP53 protein [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Gemcitabine; Nicotine inhibits the reaction [Gemcitabine results in increased expression of TP53 protein] Gemcitabine affects the activity of TP53 protein
CTD
PMID:12082016 PMID:16601104 PMID:17671697 PMID:21489314 PMID:35435491
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tp53bp1
tumor protein p53 binding protein 1
increases expression
ISO
Gemcitabine results in increased expression of TP53BP1 mRNA
CTD
PMID:17039268
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
G
Tp53inp1
tumor protein p53 inducible nuclear protein 1
increases expression
ISO
Gemcitabine results in increased expression of TP53INP1 mRNA
CTD
PMID:16570353 PMID:17039268
NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968
G
Traf1
TNF receptor-associated factor 1
affects expression
ISO
Gemcitabine affects the expression of TRAF1 mRNA
CTD
PMID:17039268
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
G
Tube1
tubulin, epsilon 1
increases expression
ISO
Gemcitabine results in increased expression of TUBE1 mRNA
CTD
PMID:17039268
NCBI chr20:42,552,390...42,570,324
Ensembl chr20:42,552,437...42,570,314
G
Tymp
thymidine phosphorylase
affects response to substance multiple interactions
ISO
TYMP protein affects the susceptibility to Gemcitabine [TYMP protein co-treated with DPYD protein] affects the susceptibility to Gemcitabine; TYMP protein affects the susceptibility to [Gemcitabine co-treated with Mitomycin]
CTD
PMID:18728667
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
G
Tyrp1
tyrosinase-related protein 1
affects expression
ISO
Gemcitabine affects the expression of TYRP1 mRNA
CTD
PMID:17039268
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
G
Ube2c
ubiquitin-conjugating enzyme E2C
decreases expression
ISO
Gemcitabine results in decreased expression of UBE2C mRNA
CTD
PMID:17039268
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
G
Uggt2
UDP-glucose glycoprotein glucosyltransferase 2
increases expression
ISO
Gemcitabine results in increased expression of UGGT2 mRNA
CTD
PMID:17039268
NCBI chr15:96,074,557...96,239,365
Ensembl chr15:96,074,564...96,237,806
G
Uhrf1
ubiquitin-like with PHD and ring finger domains 1
multiple interactions
ISO
[Gemcitabine results in decreased susceptibility to Gemcitabine] which results in decreased expression of UHRF1 protein; [UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; UHRF1 protein inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]
CTD
PMID:25189999
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
G
Vcam1
vascular cell adhesion molecule 1
decreases expression
ISO
Gemcitabine results in decreased expression of VCAM1 protein
CTD
PMID:20531411
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
G
Vegfa
vascular endothelial growth factor A
increases expression multiple interactions
ISO
Gemcitabine results in increased expression of VEGFA mRNA [Curcumin co-treated with Gemcitabine] results in decreased expression of VEGFA protein
CTD
PMID:17039268 PMID:17440100
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
G
Vgf
VGF nerve growth factor inducible
decreases expression
ISO
Gemcitabine results in decreased expression of VGF mRNA
CTD
PMID:17039268
NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341
G
Vldlr
very low density lipoprotein receptor
increases expression
ISO
Gemcitabine results in increased expression of VLDLR mRNA
CTD
PMID:17039268
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
G
Vmp1
vacuole membrane protein 1
increases expression
ISO
Gemcitabine results in increased expression of VMP1
CTD
PMID:20299819
NCBI chr10:71,405,058...71,505,045
Ensembl chr10:71,405,452...71,505,007
G
Vwf
von Willebrand factor
decreases expression
ISO
Gemcitabine results in decreased expression of VWF protein
CTD
PMID:20531411
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
G
Wnt5a
Wnt family member 5A
decreases expression
ISO
Gemcitabine results in decreased expression of WNT5A mRNA
CTD
PMID:17039268
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
G
Xbp1
X-box binding protein 1
multiple interactions
ISO
Gemcitabine promotes the reaction [1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1H-indole results in increased expression of XBP1 mRNA]; Gemcitabine promotes the reaction [arachidonylcyclopropylamide results in increased expression of XBP1 mRNA]; Gemcitabine promotes the reaction [Rimonabant results in increased expression of XBP1 mRNA]
CTD
PMID:21525939
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
G
Xiap
X-linked inhibitor of apoptosis
affects response to substance
ISO
XIAP affects the susceptibility to Gemcitabine
CTD
PMID:16628085
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
G
Yap1
Yes1 associated transcriptional regulator
multiple interactions affects response to substance
ISO
SFN protein affects the reaction [YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine]]; YAP1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]; YAP1 protein affects the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine] YAP1 protein affects the susceptibility to Gemcitabine
CTD
PMID:26894857
NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
G
Zfp110
zinc finger protein 110
increases expression
ISO
Gemcitabine results in increased expression of ZNF274 mRNA
CTD
PMID:17039268
NCBI chr 1:73,445,303...73,461,112
Ensembl chr 1:73,445,336...73,461,086
G
Zfp449
zinc finger protein 449
increases expression
ISO
Gemcitabine results in increased expression of ZNF449 mRNA
CTD
PMID:17039268
NCBI chr X:134,120,820...134,140,921
Ensembl chr X:134,122,636...134,140,924
G
Zfp521
zinc finger protein 521
decreases expression
ISO
Gemcitabine results in decreased expression of ZNF521 mRNA
CTD
PMID:17039268
NCBI chr18:4,775,952...5,068,592
Ensembl chr18:4,787,295...5,068,458
G
Agtr1b
angiotensin II receptor, type 1b
increases expression
ISO
Hydroxyurea results in increased expression of AGTR1B mRNA
CTD
PMID:27208086
NCBI chr 2:102,844,969...102,920,232
Ensembl chr 2:102,844,969...102,920,232
G
Aldoc
aldolase, fructose-bisphosphate C
multiple interactions
ISO
Hydroxyurea promotes the reaction [4-hydroxy-2-nonenal binds to ALDOA protein]
CTD
PMID:20889679
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
G
Alox5
arachidonate 5-lipoxygenase
multiple interactions
ISO
Hydroxyurea inhibits the reaction [L 708714 binds to ALOX5 protein]
CTD
PMID:7577949
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
G
Apaf1
apoptotic peptidase activating factor 1
increases expression
ISO
Hydroxyurea results in increased expression of APAF1 mRNA
CTD
PMID:27208086
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
G
Atm
ATM serine/threonine kinase
increases expression increases phosphorylation multiple interactions
ISO
Hydroxyurea results in increased expression of ATM mRNA Hydroxyurea results in increased phosphorylation of ATM protein Doxorubicin inhibits the reaction [Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]]; Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]
CTD
PMID:27208086 PMID:31597699
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
G
Atp6v0a2
ATPase H+ transporting V0 subunit a2
decreases expression
ISO
Hydroxyurea results in decreased expression of ATP6V0A2 mRNA
CTD
PMID:34748853
NCBI chr12:31,947,220...31,979,875
Ensembl chr12:31,822,733...32,007,069
G
Atp6v1f
ATPase H+ transporting V1 subunit F
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of ATP6V1F gene
CTD
PMID:16868089
NCBI chr 4:58,067,666...58,070,628
G
Atr
ATR serine/threonine kinase
multiple interactions
ISO
[4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine results in decreased activity of ATR] which results in increased susceptibility to Hydroxyurea; Caffeine inhibits the reaction [Hydroxyurea promotes the reaction [ATR protein results in increased phosphorylation of and results in increased activity of CHEK1 protein]]
CTD
PMID:18158334 PMID:21730979
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
G
Atxn1
ataxin 1
decreases expression
ISO
Hydroxyurea results in decreased expression of ATXN1 mRNA
CTD
PMID:24211769
NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360
G
Bax
BCL2 associated X, apoptosis regulator
increases expression
ISO
Hydroxyurea results in increased expression of BAX mRNA
CTD
PMID:16005713 PMID:16356682
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Bbc3
Bcl-2 binding component 3
increases expression
ISO
Hydroxyurea results in increased expression of BBC3 mRNA
CTD
PMID:27208086
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
G
Bcl2l1
Bcl2-like 1
decreases response to substance
EXP
BCL2L1 gene mutant form results in decreased susceptibility to Hydroxyurea
CTD
PMID:10970895
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
G
Bik
BCL2-interacting killer
increases expression
ISO
Hydroxyurea results in increased expression of BIK mRNA
CTD
PMID:27208086
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
G
Blm
BLM RecQ like helicase
increases expression decreases expression
ISO
Hydroxyurea results in increased expression of BLM mRNA Hydroxyurea results in decreased expression of BLM mRNA
CTD
PMID:18647660 PMID:24211769
NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312
G
Bmi1
BMI1 proto-oncogene, polycomb ring finger
decreases expression
ISO
Hydroxyurea results in decreased expression of BMI1 mRNA
CTD
PMID:12929121
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
G
Bora
bora, aurora kinase A activator
decreases expression
ISO
Hydroxyurea results in decreased expression of BORA mRNA
CTD
PMID:17374387
NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
G
Bpnt1
3'(2'), 5'-bisphosphate nucleotidase 1
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of BPNT1 gene
CTD
PMID:16868089
NCBI chr13:96,865,634...96,893,506
Ensembl chr13:96,868,580...96,893,503
G
Bscl2
BSCL2 lipid droplet biogenesis associated, seipin
increases expression
ISO
Hydroxyurea results in increased expression of BSCL2 mRNA
CTD
PMID:22003191
NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421
G
Btg2
BTG anti-proliferation factor 2
increases expression
ISO
Hydroxyurea results in increased expression of BTG2 mRNA
CTD
PMID:24211769
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
G
Btg3
BTG anti-proliferation factor 3
decreases expression
ISO
Hydroxyurea results in decreased expression of BTG3 mRNA
CTD
PMID:24211769
NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170
G
Casp3
caspase 3
multiple interactions increases activity increases cleavage increases expression
ISO
[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; [Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; Bucladesine promotes the reaction [Hydroxyurea results in increased activity of CASP3 protein]; Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]; Hydroxyurea promotes the reaction [Valproic Acid results in increased cleavage of CASP3 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]] Hydroxyurea results in increased cleavage of CASP3 protein Selegiline promotes the reaction [Hydroxyurea results in increased cleavage of CASP3 protein]; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased cleavage of CASP3 protein] Hydroxyurea results in increased expression of CASP3 protein
CTD
PMID:10697531 PMID:16005713 PMID:17653085 PMID:23696560 PMID:26399158 PMID:29228353 PMID:31597699 More...
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Casp7
caspase 7
increases expression
ISO
Hydroxyurea results in increased expression of CASP7 mRNA
CTD
PMID:27208086
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
G
Casp8
caspase 8
increases expression
ISO
Hydroxyurea results in increased expression of CASP8 protein
CTD
PMID:26399158
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
G
Casp9
caspase 9
increases expression
ISO
Hydroxyurea results in increased expression of CASP9 protein
CTD
PMID:26399158
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
G
Ccdc51
coiled-coil domain containing 51
decreases expression
ISO
Hydroxyurea results in decreased expression of CCDC51 mRNA
CTD
PMID:24211769
NCBI chr 8:109,722,595...109,741,478
Ensembl chr 8:109,722,557...109,741,472
G
Ccna2
cyclin A2
increases expression
ISO
Hydroxyurea results in increased expression of CCNA2 protein
CTD
PMID:11468187
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
G
Ccnb1
cyclin B1
increases expression decreases expression
ISO
Hydroxyurea results in increased expression of CCNB1 protein Hydroxyurea results in decreased expression of CCNB1 protein
CTD
PMID:11468187 PMID:16356682
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnd1
cyclin D1
increases expression decreases expression
ISO
Hydroxyurea results in increased expression of CCND1 protein Hydroxyurea results in decreased expression of CCND1 protein
CTD
PMID:11468187 PMID:16356682
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Ccnd2
cyclin D2
increases expression
ISO
Hydroxyurea results in increased expression of CCND2 protein
CTD
PMID:11468187
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
G
Ccnd3
cyclin D3
increases expression
ISO
Hydroxyurea results in increased expression of CCND3 protein
CTD
PMID:11468187
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
G
Ccne1
cyclin E1
increases expression
ISO
Hydroxyurea results in increased expression of CCNE1 protein Hydroxyurea results in increased expression of CCNE1 mRNA
CTD
PMID:11468187 PMID:27208086
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
G
Ccne2
cyclin E2
decreases expression
ISO
Hydroxyurea results in decreased expression of CCNE2 mRNA
CTD
PMID:12929121
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
G
Ccng1
cyclin G1
increases expression
ISO
Hydroxyurea results in increased expression of CCNG1 mRNA
CTD
PMID:16005713 PMID:27208086
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
G
Ccng2
cyclin G2
increases expression
ISO
Hydroxyurea results in increased expression of CCNG2 mRNA
CTD
PMID:12929121
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
G
Cdc25a
cell division cycle 25A
increases expression
ISO
Hydroxyurea results in increased expression of CDC25A mRNA
CTD
PMID:12929121
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
G
Cdca8
cell division cycle associated 8
decreases expression
ISO
Hydroxyurea results in decreased expression of CDCA8 mRNA
CTD
PMID:17374387
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
G
Cdk4
cyclin-dependent kinase 4
decreases expression
ISO
Hydroxyurea results in decreased expression of CDK4 protein
CTD
PMID:16356682
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
G
Cdk5r1
cyclin-dependent kinase 5 regulatory subunit 1
increases expression
ISO
Hydroxyurea results in increased expression of CDK5R1 mRNA
CTD
PMID:33770205
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
G
Cdk5rap1
CDK5 regulatory subunit associated protein 1
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of CDK5RAP1 gene
CTD
PMID:16868089
NCBI chr 3:142,838,081...142,872,669
Ensembl chr 3:142,708,028...142,872,677
G
Cdkn1a
cyclin-dependent kinase inhibitor 1A
multiple interactions increases expression
ISO EXP
[Valproic Acid co-treated with Hydroxyurea] results in increased expression of CDKN1A mRNA; Hydroxyurea inhibits the reaction [trichostatin A results in increased expression of CDKN1A protein]; Hydroxyurea inhibits the reaction [Valproic Acid results in increased expression of CDKN1A protein] Hydroxyurea results in increased expression of CDKN1A protein Hydroxyurea results in increased expression of CDKN1A mRNA; Hydroxyurea results in increased expression of CDKN1A protein TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of CDKN1A mRNA]
CTD
PMID:10961388 PMID:10978678 PMID:15557822 PMID:16005713 PMID:17653085 PMID:18647660 PMID:21840268 PMID:24211769 PMID:27208086 PMID:29228353 More...
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
G
Cdkn1b
cyclin-dependent kinase inhibitor 1B
increases expression multiple interactions
ISO
Hydroxyurea results in increased expression of CDKN1B protein [Valproic Acid co-treated with Hydroxyurea] results in increased expression of CDKN1B mRNA
CTD
PMID:10961388 PMID:17653085
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
G
Cdkn1c
cyclin-dependent kinase inhibitor 1C
increases expression
ISO
Hydroxyurea results in increased expression of CDKN1C mRNA
CTD
PMID:12929121
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
G
Cdkn2a
cyclin-dependent kinase inhibitor 2A
multiple interactions increases expression
ISO
Hydroxyurea inhibits the reaction [Azacitidine results in decreased methylation of CDKN2A gene]; Hydroxyurea inhibits the reaction [decitabine results in decreased methylation of CDKN2A gene] Hydroxyurea results in increased expression of CDKN2A protein
CTD
PMID:10961388 PMID:17686055
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
G
Cdkn2b
cyclin-dependent kinase inhibitor 2B
increases expression
ISO
Hydroxyurea results in increased expression of CDKN2B mRNA
CTD
PMID:27208086
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
G
Cemip2
cell migration inducing hyaluronidase 2
decreases expression
ISO
Hydroxyurea results in decreased expression of CEMIP2 mRNA
CTD
PMID:33770205
NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760
G
Chchd3
coiled-coil-helix-coiled-coil-helix domain containing 3
decreases expression
ISO
Hydroxyurea results in decreased expression of CHCHD3 mRNA
CTD
PMID:12929121
NCBI chr 4:61,360,352...61,616,850
Ensembl chr 4:61,360,353...61,616,847
G
Chek1
checkpoint kinase 1
multiple interactions decreases expression increases expression increases phosphorylation
ISO
Caffeine inhibits the reaction [Hydroxyurea promotes the reaction [ATR protein results in increased phosphorylation of and results in increased activity of CHEK1 protein]] Hydroxyurea results in decreased expression of CHEK1 mRNA Hydroxyurea results in increased expression of CHK1 protein modified form Hydroxyurea results in increased phosphorylation of CHEK1 protein
CTD
PMID:12929121 PMID:18158334 PMID:21840268 PMID:32466334
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
G
Chek2
checkpoint kinase 2
increases expression increases phosphorylation
ISO
Hydroxyurea results in increased expression of CHEK2 protein modified form Hydroxyurea results in increased phosphorylation of CHEK2 protein
CTD
PMID:21840268 PMID:32466334
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
G
Cideb
cell death-inducing DFFA-like effector b
decreases expression
ISO
Hydroxyurea results in decreased expression of CIDEB mRNA
CTD
PMID:12929121
NCBI chr15:29,252,208...29,256,482
Ensembl chr15:29,252,213...29,256,605
G
Cks2
CDC28 protein kinase regulatory subunit 2
decreases expression
ISO
Hydroxyurea results in decreased expression of CKS2 mRNA
CTD
PMID:17374387
NCBI chr17:13,570,611...13,575,770
G
Cln8
CLN8, transmembrane ER and ERGIC protein
decreases expression
ISO
Hydroxyurea results in decreased expression of CLN8 mRNA
CTD
PMID:24211769
NCBI chr16:74,749,662...74,759,553
Ensembl chr16:74,749,662...74,759,774
G
Coa7
cytochrome c oxidase assembly factor 7
decreases expression
ISO
Hydroxyurea results in decreased expression of COA7 mRNA
CTD
PMID:24211769
NCBI chr 5:123,069,356...123,080,942
Ensembl chr 5:123,069,371...123,080,199
G
Col1a2
collagen type I alpha 2 chain
affects expression
ISO
Hydroxyurea affects the expression of COL1A2 mRNA
CTD
PMID:24704097
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
G
Cpb2
carboxypeptidase B2
decreases expression
ISO
Hydroxyurea results in decreased expression of CPB2 mRNA
CTD
PMID:12929121
NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556
G
Cpt2
carnitine palmitoyltransferase 2
decreases expression
ISO
Hydroxyurea results in decreased expression of CPT2 mRNA
CTD
PMID:24211769
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
G
Cradd
CASP2 and RIPK1 domain containing adaptor with death domain
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of CRADD gene
CTD
PMID:16868089
NCBI chr 7:29,940,240...29,952,907
Ensembl chr 7:29,798,586...29,952,907
G
Csta
cystatin A
affects expression
ISO
Hydroxyurea affects the expression of CSTA mRNA
CTD
PMID:27825931
NCBI chr11:64,620,483...64,631,488
Ensembl chr11:64,620,483...64,631,488
G
Cxcr1
C-X-C motif chemokine receptor 1
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of CXCR1 gene
CTD
PMID:16868089
NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084
G
Cyp26a1
cytochrome P450, family 26, subfamily a, polypeptide 1
increases expression
ISO
Hydroxyurea results in increased expression of CYP26A1 mRNA
CTD
PMID:29990529
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
G
Dapk1
death associated protein kinase 1
increases expression
ISO
Hydroxyurea results in increased expression of DAPK1 mRNA
CTD
PMID:27208086
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
G
Dclre1c
DNA cross-link repair 1C
increases response to substance
ISO
DCLRE1C results in increased susceptibility to Hydroxyurea
CTD
PMID:21785230
NCBI chr17:74,775,828...74,810,089
Ensembl chr17:74,776,935...74,809,186
G
Ddb2
damage specific DNA binding protein 2
increases expression
ISO
Hydroxyurea results in increased expression of DDB2 mRNA
CTD
PMID:18647660
NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
G
Ddit4l
DNA-damage-inducible transcript 4-like
increases expression
ISO
Hydroxyurea results in increased expression of DDIT4L mRNA
CTD
PMID:27208086
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
G
Dlgap1
DLG associated protein 1
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of DLGAP1 gene
CTD
PMID:16868089
NCBI chr 9:109,857,500...110,726,817
Ensembl chr 9:110,167,448...110,726,817
G
Dnmt1
DNA methyltransferase 1
affects response to substance
ISO
DNMT1 protein affects the susceptibility to Hydroxyurea
CTD
PMID:17991895
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
G
Dym
dymeclin
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of DYM gene
CTD
PMID:16868089
NCBI chr18:68,605,131...68,900,905
Ensembl chr18:68,605,185...68,900,903
G
E2f1
E2F transcription factor 1
decreases expression
ISO
Hydroxyurea results in decreased expression of E2F1 mRNA
CTD
PMID:24211769
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
G
E2f8
E2F transcription factor 8
increases expression
ISO
Hydroxyurea results in increased expression of E2F8 mRNA
CTD
PMID:33770205
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
G
Ech1
enoyl-CoA hydratase 1
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of ECH1 gene
CTD
PMID:16868089
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
G
Eda2r
ectodysplasin A2 receptor
increases expression
ISO
Hydroxyurea results in increased expression of EDA2R mRNA
CTD
PMID:27208086
NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268
G
Edn3
endothelin 3
decreases expression
ISO
Hydroxyurea results in decreased expression of EDN3 protein
CTD
PMID:15020278
NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093
G
Epo
erythropoietin
increases expression
ISO
Hydroxyurea results in increased expression of EPO protein
CTD
PMID:19724057
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
G
Ercc5
ERCC excision repair 5, endonuclease
increases expression
ISO
Hydroxyurea results in increased expression of ERCC5 mRNA
CTD
PMID:12929121
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
G
Errfi1
ERBB receptor feedback inhibitor 1
decreases expression
ISO
Hydroxyurea results in decreased expression of ERRFI1 mRNA
CTD
PMID:33770205
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
G
Eva1c
eva-1 homolog C
increases expression
ISO
Hydroxyurea results in increased expression of EVA1C mRNA
CTD
PMID:27208086
NCBI chr11:30,089,510...30,163,596
Ensembl chr11:30,089,365...30,163,596
G
Fancd2
FA complementation group D2
multiple interactions
ISO
[arsenic trioxide results in decreased activity of FANCD2 protein] which results in increased susceptibility to Hydroxyurea; [monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to Hydroxyurea
CTD
PMID:25092648
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
G
Fas
Fas cell surface death receptor
increases expression multiple interactions
ISO
Hydroxyurea results in increased expression of FAS mRNA Hydroxyurea results in increased expression of FAS mRNA; Hydroxyurea results in increased expression of FAS protein TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of FAS mRNA]
CTD
PMID:16005713 PMID:16356682 PMID:26399158 PMID:27208086 PMID:29228353
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
G
Faslg
Fas ligand
increases expression
ISO
Hydroxyurea results in increased expression of FASL mRNA; Hydroxyurea results in increased expression of FASL protein
CTD
PMID:16356682 PMID:26399158
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
G
Fgf8
fibroblast growth factor 8
increases expression
ISO
Hydroxyurea results in increased expression of FGF8 mRNA
CTD
PMID:29990529
NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359
G
Fkbp3
FKBP prolyl isomerase 3
increases expression
ISO
Hydroxyurea results in increased expression of FKBP3 mRNA
CTD
PMID:12929121
NCBI chr 6:83,113,885...83,125,500
Ensembl chr 6:83,113,786...83,127,011
G
Fos
Fos proto-oncogene, AP-1 transcription factor subunit
multiple interactions
ISO
Hydroxyurea results in increased expression of and results in increased activity of FOS protein
CTD
PMID:15772364
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
G
Foxj2
forkhead box J2
decreases expression
ISO
Hydroxyurea results in decreased expression of FOXJ2 mRNA
CTD
PMID:24211769
NCBI chr 4:156,047,043...156,073,540
Ensembl chr 4:156,046,969...156,073,518
G
Foxo1
forkhead box O1
increases expression
ISO
Hydroxyurea results in increased expression of FOXO1 mRNA
CTD
PMID:27208086
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
G
Fzd1
frizzled class receptor 1
decreases expression
ISO
Hydroxyurea results in decreased expression of FZD1 mRNA
CTD
PMID:24211769
NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
G
Gadd45a
growth arrest and DNA-damage-inducible, alpha
increases expression
ISO
Hydroxyurea results in increased expression of GADD45A mRNA
CTD
PMID:18647660 PMID:27208086
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
G
Galnt16
polypeptide N-acetylgalactosaminyltransferase 16
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of GALNT16 gene
CTD
PMID:16868089
NCBI chr 6:100,168,943...100,250,718
Ensembl chr 6:100,170,306...100,250,705
G
Gapdh
glyceraldehyde-3-phosphate dehydrogenase
affects localization multiple interactions decreases activity
ISO
Hydroxyurea affects the localization of GAPDH protein [Hydroxyurea promotes the reaction [4-hydroxy-2-nonenal binds to GAPDH protein]] which results in decreased activity of GAPDH protein; [Hydroxyurea results in increased abundance of Free Radicals] promotes the reaction [4-hydroxy-2-nonenal binds to GAPDH protein]; Hydroxyurea affects the metabolism of and results in decreased activity of and affects the localization of GAPDH protein; Hydroxyurea promotes the reaction [4-hydroxy-2-nonenal binds to GAPDH protein]; Selegiline inhibits the reaction [Hydroxyurea affects the localization of GAPDH protein] Hydroxyurea results in decreased activity of GAPDH protein
CTD
PMID:20889679 PMID:23696560
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
G
Gdf15
growth differentiation factor 15
increases expression
ISO
Hydroxyurea results in increased expression of GDF15 mRNA
CTD
PMID:24211769
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
G
Gen1
GEN1 Holliday junction 5' flap endonuclease
increases expression
ISO
Hydroxyurea results in increased expression of GEN1 protein
CTD
PMID:24980922
NCBI chr 6:33,947,599...33,978,461
Ensembl chr 6:33,948,206...33,978,401
G
Got2
glutamic-oxaloacetic transaminase 2
multiple interactions
ISO
Hydroxyurea promotes the reaction [4-hydroxy-2-nonenal binds to GOT2 protein]
CTD
PMID:20889679
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
G
Grb14
growth factor receptor bound protein 14
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of GRB14 gene
CTD
PMID:16868089
NCBI chr 3:49,568,210...49,683,805
Ensembl chr 3:49,568,210...49,683,889
G
Grin1
glutamate ionotropic receptor NMDA type subunit 1
decreases expression
ISO
Hydroxyurea results in decreased expression of GRIN1 mRNA
CTD
PMID:34748853
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
G
Grpel1
GrpE-like 1, mitochondrial
decreases expression
ISO
Hydroxyurea results in decreased expression of GRPEL1 mRNA
CTD
PMID:24211769
NCBI chr14:74,292,023...74,298,243
Ensembl chr14:74,292,023...74,298,200
G
H2ax
H2A.X variant histone
increases expression increases phosphorylation multiple interactions
ISO
Hydroxyurea results in increased expression of H2AX protein; Hydroxyurea results in increased expression of H2AX protein modified form Hydroxyurea results in increased phosphorylation of H2AX protein TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased phosphorylation of H2AX protein]
CTD
PMID:21840268 PMID:25125662 PMID:25130544 PMID:29228353 PMID:32466334 PMID:32482060 More...
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
G
Hbp1
HMG-box transcription factor 1
decreases expression
ISO
Hydroxyurea results in decreased expression of HBP1 mRNA
CTD
PMID:24211769
NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787
G
Hdac2
histone deacetylase 2
multiple interactions
ISO
Hydroxyurea promotes the reaction [Valproic Acid results in decreased expression of HDAC2 protein]
CTD
PMID:17653085
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
G
Hesx1
HESX homeobox 1
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of HESX1 gene
CTD
PMID:16868089
NCBI chr16:2,191,852...2,193,957
Ensembl chr16:2,191,852...2,193,957
G
Hoxb9
homeo box B9
decreases expression
ISO
Hydroxyurea results in decreased expression of HOXB9 mRNA
CTD
PMID:29990529
NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
G
Hoxc6
homeo box C6
decreases expression
ISO
Hydroxyurea results in decreased expression of HOXC6 mRNA
CTD
PMID:29990529
NCBI chr 7:134,138,017...134,148,899
Ensembl chr 7:134,135,502...134,148,392
G
Hspa8
heat shock protein family A (Hsp70) member 8
increases expression
ISO
Hydroxyurea results in increased expression of HSPA8 mRNA
CTD
PMID:18647660
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
G
Ier3
immediate early response 3
increases expression
ISO
Hydroxyurea results in increased expression of IER3 mRNA
CTD
PMID:12929121
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
G
Il13
interleukin 13
affects expression
ISO
Hydroxyurea affects the expression of IL13 protein
CTD
PMID:15927844
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
G
Ints15
integrator complex subunit 15
decreases expression
ISO
Hydroxyurea results in decreased expression of INTS15 mRNA
CTD
PMID:24211769
NCBI chr12:11,245,045...11,260,170
Ensembl chr12:11,245,842...11,260,166
G
Isg20l2
interferon stimulated exonuclease gene 20-like 2
decreases expression
ISO
Hydroxyurea results in decreased expression of ISG20L2 mRNA
CTD
PMID:24211769
NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614
G
Itih2
inter-alpha-trypsin inhibitor heavy chain 2
increases expression
ISO
Hydroxyurea results in increased expression of ITIH2 mRNA
CTD
PMID:12929121
NCBI chr17:68,375,574...68,411,849
Ensembl chr17:68,375,567...68,411,841
G
Kat2b
lysine acetyltransferase 2B
increases expression
ISO
Hydroxyurea results in increased expression of KAT2B mRNA
CTD
PMID:27208086
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
G
Kif20a
kinesin family member 20A
decreases expression
ISO
Hydroxyurea results in decreased expression of KIF20A mRNA
CTD
PMID:24211769
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
G
Kif3b
kinesin family member 3B
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of KIF3B gene
CTD
PMID:16868089
NCBI chr 3:141,758,466...141,798,012
Ensembl chr 3:141,758,466...141,797,963
G
Klrb1a
killer cell lectin like receptor B1A
increases expression
ISO
Hydroxyurea results in increased expression of KLRB1A mRNA
CTD
PMID:12929121
NCBI chr 4:161,890,577...161,904,050
Ensembl chr 4:161,890,577...161,961,675
G
Kpna2
karyopherin subunit alpha 2
decreases expression
ISO
Hydroxyurea results in decreased expression of KPNA2 mRNA
CTD
PMID:17374387
NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
G
Kras
KRAS proto-oncogene, GTPase
decreases expression
ISO
Hydroxyurea results in decreased expression of KRAS mRNA
CTD
PMID:12929121
NCBI chr 4:178,185,418...178,218,484
G
Lhx2
LIM homeobox 2
decreases expression
ISO
Hydroxyurea results in decreased expression of LHX2 mRNA
CTD
PMID:24211769
NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908
G
Liph
lipase H
decreases expression
ISO
Hydroxyurea results in decreased expression of LIPH mRNA
CTD
PMID:33770205
NCBI chr11:79,032,229...79,081,625
Ensembl chr11:79,033,312...79,081,625
G
Lpo
lactoperoxidase
decreases expression
ISO
Hydroxyurea results in decreased expression of LPO mRNA
CTD
PMID:34748853
NCBI chr10:72,606,950...72,626,220
Ensembl chr10:72,606,944...72,626,535
G
Lrrc47
leucine rich repeat containing 47
decreases expression
ISO
Hydroxyurea results in decreased expression of LRRC47 mRNA
CTD
PMID:24211769
NCBI chr 5:164,570,539...164,580,174
Ensembl chr 5:164,570,435...164,580,174
G
Ltb4r
leukotriene B4 receptor
increases expression
ISO
Hydroxyurea results in increased expression of LTB4R1 mRNA
CTD
PMID:27208086
NCBI chr15:29,263,199...29,265,716
G
Mad2l1
mitotic arrest deficient 2 like 1
decreases expression
ISO
Hydroxyurea results in decreased expression of MAD2L1 mRNA
CTD
PMID:12929121
NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470
G
Mad2l2
mitotic arrest deficient 2 like 2
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of MAD2L2 gene
CTD
PMID:16868089
NCBI chr 5:158,563,545...158,576,698
Ensembl chr 5:158,563,567...158,576,693
G
Mapk1
mitogen activated protein kinase 1
decreases phosphorylation
EXP
Hydroxyurea results in decreased phosphorylation of MAPK1 protein
CTD
PMID:15557822
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
G
Mapk3
mitogen activated protein kinase 3
decreases phosphorylation
EXP
Hydroxyurea results in decreased phosphorylation of MAPK3 protein
CTD
PMID:15557822
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
G
Mapk8
mitogen-activated protein kinase 8
decreases phosphorylation
EXP
Hydroxyurea results in decreased phosphorylation of MAPK8 protein
CTD
PMID:15557822
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
G
Mdm2
MDM2 proto-oncogene
increases expression affects expression
ISO
Hydroxyurea results in increased expression of MDM2 mRNA Hydroxyurea affects the expression of MDM2 protein
CTD
PMID:16356682 PMID:18647660
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
G
Mecom
MDS1 and EVI1 complex locus
increases expression
ISO
Hydroxyurea results in increased expression of MECOM protein mutant form
CTD
PMID:16532439
NCBI chr 2:112,909,353...113,464,583
Ensembl chr 2:112,909,321...113,464,590
G
Mgmt
O-6-methylguanine-DNA methyltransferase
increases expression
ISO
Hydroxyurea results in increased expression of MGMT mRNA
CTD
PMID:12929121
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
G
Mipol1
mirror-image polydactyly 1
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of MIPOL1 gene
CTD
PMID:16868089
NCBI chr 6:74,755,293...75,090,403
Ensembl chr 6:74,755,395...75,086,811
G
Mpg
N-methylpurine-DNA glycosylase
increases expression
ISO
Hydroxyurea results in increased expression of MPG mRNA
CTD
PMID:12929121
NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
G
Mpzl1
myelin protein zero-like 1
decreases expression
ISO
Hydroxyurea results in decreased expression of MPZL1 mRNA
CTD
PMID:24211769
NCBI chr13:77,852,467...77,889,305
Ensembl chr13:77,852,467...77,896,616
G
Mrm2
mitochondrial rRNA methyltransferase 2
decreases expression
ISO
Hydroxyurea results in decreased expression of MRM2 mRNA
CTD
PMID:24211769
NCBI chr12:14,309,556...14,314,759
Ensembl chr12:14,251,941...14,314,118
G
Msh6
mutS homolog 6
decreases expression
ISO
Hydroxyurea results in decreased expression of MSH6 mRNA
CTD
PMID:24211769
NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956
G
Mtor
mechanistic target of rapamycin kinase
decreases expression
ISO
Hydroxyurea results in decreased expression of MTOR mRNA
CTD
PMID:34748853
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
G
Mxi1
MAX interactor 1, dimerization protein
decreases expression
ISO
Hydroxyurea results in decreased expression of MXI1 mRNA
CTD
PMID:33770205
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
G
Myb
MYB proto-oncogene, transcription factor
decreases expression
ISO
Hydroxyurea results in decreased expression of MYB mRNA
CTD
PMID:12929121
NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
G
Myo1e
myosin IE
decreases expression
ISO
Hydroxyurea results in decreased expression of MYO1E mRNA
CTD
PMID:33770205
NCBI chr 8:70,887,934...71,080,180
Ensembl chr 8:70,887,870...71,080,169
G
Nampt
nicotinamide phosphoribosyltransferase
decreases expression
ISO
Hydroxyurea results in decreased expression of NAMPT mRNA
CTD
PMID:12929121
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
G
Nek3
NIMA-related kinase 3
decreases expression
ISO
Hydroxyurea results in decreased expression of NEK3 mRNA
CTD
PMID:12929121
NCBI chr16:69,867,020...69,892,477
Ensembl chr16:69,867,047...69,892,508
G
Neurod4
neuronal differentiation 4
decreases expression
ISO
Hydroxyurea results in decreased expression of NEUROD4 mRNA
CTD
PMID:12929121
NCBI chr 7:7,090,048...7,102,018
Ensembl chr 7:7,090,045...7,102,030
G
Nfe2l2
NFE2 like bZIP transcription factor 2
decreases expression
ISO
Hydroxyurea results in decreased expression of NFE2L2 mRNA
CTD
PMID:34748853
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
G
Nfkb1
nuclear factor kappa B subunit 1
increases expression decreases expression
ISO
Hydroxyurea results in increased expression of NFKB1 mRNA Hydroxyurea results in decreased expression of NFKB1 mRNA
CTD
PMID:18647660 PMID:34748853
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
G
Nfkbia
NFKB inhibitor alpha
increases expression
ISO
Hydroxyurea results in increased expression of NFKBIA mRNA
CTD
PMID:18647660
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
G
Nop58
NOP58 ribonucleoprotein
decreases expression
ISO
Hydroxyurea results in decreased expression of NOL5 mRNA
CTD
PMID:12929121
NCBI chr 9:61,120,939...61,144,810
Ensembl chr 9:61,120,929...61,144,810
G
Notch1
notch receptor 1
multiple interactions decreases expression
ISO
Doxorubicin inhibits the reaction [Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]]; Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]]
CTD
PMID:31597699
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
G
Nudt12
nudix hydrolase 12
increases expression
ISO
Hydroxyurea results in increased expression of NUDT12 mRNA
CTD
PMID:12929121
NCBI chr 9:98,741,627...98,755,039
Ensembl chr 9:98,742,360...98,755,039
G
Nus1
NUS1 dehydrodolichyl diphosphate synthase subunit
decreases expression
ISO
Hydroxyurea results in decreased expression of NUS1 mRNA
CTD
PMID:12929121
NCBI chr20:31,811,817...31,838,562
Ensembl chr20:31,811,817...31,838,561
G
Olig2
oligodendrocyte transcription factor 2
decreases expression
ISO
Hydroxyurea results in decreased expression of OLIG2 mRNA
CTD
PMID:34748853
NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152
G
P2ry6
pyrimidinergic receptor P2Y6
increases expression
ISO
Hydroxyurea results in increased expression of P2RY6 mRNA
CTD
PMID:27208086
NCBI chr 1:155,295,110...155,330,610
Ensembl chr 1:155,295,111...155,330,808
G
Pcna
proliferating cell nuclear antigen
increases expression
ISO
Hydroxyurea results in increased expression of PCNA mRNA
CTD
PMID:18647660
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
G
Pelo
pelota mRNA surveillance and ribosome rescue factor
decreases expression
ISO
Hydroxyurea results in decreased expression of PELO mRNA
CTD
PMID:24211769
NCBI chr 2:46,797,853...46,799,621
Ensembl chr 2:46,797,853...46,799,746
G
Perp
p53 apoptosis effector related to PMP22
increases expression
ISO
Hydroxyurea results in increased expression of PERP mRNA
CTD
PMID:27208086
NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511
G
Phlda3
pleckstrin homology-like domain, family A, member 3
increases expression
ISO
Hydroxyurea results in increased expression of PHLDA3 mRNA
CTD
PMID:24211769
NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335
G
Pidd1
p53-induced death domain protein 1
increases expression
ISO
Hydroxyurea results in increased expression of PIDD1 mRNA
CTD
PMID:27208086
NCBI chr 1:196,536,815...196,542,808
Ensembl chr 1:196,536,834...196,542,699
G
Pklr
pyruvate kinase L/R
decreases expression
ISO
Hydroxyurea results in decreased expression of PKLR mRNA
CTD
PMID:12929121
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
G
Plk1
polo-like kinase 1
multiple interactions decreases phosphorylation
ISO
[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein; Doxorubicin affects the reaction [[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein] Hydroxyurea results in decreased phosphorylation of PLK1 protein
CTD
PMID:31597699
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
G
Pmaip1
phorbol-12-myristate-13-acetate-induced protein 1
increases expression multiple interactions
ISO
Hydroxyurea results in increased expression of PMAIP1 mRNA TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of PMAIP1 mRNA]
CTD
PMID:27208086 PMID:29228353
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
G
Pml
PML nuclear body scaffold
increases expression
ISO
Hydroxyurea results in increased expression of PML mRNA
CTD
PMID:27208086
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
G
Polh
DNA polymerase eta
increases expression
ISO
Hydroxyurea results in increased expression of POLH mRNA
CTD
PMID:25125662
NCBI chr 9:14,778,355...14,813,210
Ensembl chr 9:14,777,888...14,812,723
G
Ppm1d
protein phosphatase, Mg2+/Mn2+ dependent, 1D
increases expression
ISO
Hydroxyurea results in increased expression of PPM1D mRNA
CTD
PMID:24211769
NCBI chr10:70,172,603...70,208,607
Ensembl chr10:70,172,603...70,208,607
G
Ppp1r12a
protein phosphatase 1, regulatory subunit 12A
decreases expression
ISO
Hydroxyurea results in decreased expression of PPP1R12A mRNA
CTD
PMID:12929121
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
G
Prc1
protein regulator of cytokinesis 1
decreases expression
ISO
Hydroxyurea results in decreased expression of PRC1 mRNA
CTD
PMID:17374387
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
G
Prkab1
protein kinase AMP-activated non-catalytic subunit beta 1
increases expression
ISO
Hydroxyurea results in increased expression of PRKAB1 mRNA
CTD
PMID:24211769
NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661
G
Prrg4
proline rich and Gla domain 4
increases expression
ISO
Hydroxyurea results in increased expression of PRRG4 mRNA
CTD
PMID:27208086
NCBI chr 3:91,214,646...91,243,347
Ensembl chr 3:91,214,653...91,243,273
G
Prune1
prune exopolyphosphatase 1
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of PRUNE1 gene
CTD
PMID:16868089
NCBI chr 2:182,830,575...182,859,972
Ensembl chr 2:182,830,578...182,859,336
G
Psip1
PC4 and SRSF1 interacting protein 1
decreases expression
ISO
Hydroxyurea results in decreased expression of PSIP1 mRNA
CTD
PMID:12929121
NCBI chr 5:97,847,010...97,879,280
Ensembl chr 5:97,847,015...97,879,257
G
Psrc1
proline and serine rich coiled-coil 1
decreases expression
ISO
Hydroxyurea results in decreased expression of PSRC1 mRNA
CTD
PMID:17374387
NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874
G
Pus3
pseudouridine synthase 3
decreases expression
ISO
Hydroxyurea results in decreased expression of PUS3 mRNA
CTD
PMID:24211769
NCBI chr 8:33,910,461...33,918,716
Ensembl chr 8:33,911,357...33,918,714
G
Rab34
RAB34, member RAS oncogene family
increases expression
ISO
Hydroxyurea results in increased expression of RAB34 mRNA
CTD
PMID:12929121
NCBI chr10:63,083,319...63,087,538
Ensembl chr10:63,083,338...63,087,538
G
Rad23a
RAD23 homolog A, nucleotide excision repair protein
decreases expression
ISO
Hydroxyurea results in decreased expression of RAD23A mRNA
CTD
PMID:12929121
NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695
G
Rad51c
RAD51 paralog C
increases expression
ISO
Hydroxyurea results in increased expression of RAD51C mRNA
CTD
PMID:27825931
NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,205,032...72,231,248
G
Ran
RAN, member RAS oncogene family
decreases expression
ISO
Hydroxyurea results in decreased expression of RAN mRNA
CTD
PMID:12929121
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
G
Rap2b
RAP2B, member of RAS oncogene family
decreases expression
ISO
Hydroxyurea results in decreased expression of RAP2B mRNA
CTD
PMID:24211769
NCBI chr 2:145,599,714...145,600,265
Ensembl chr 2:145,599,116...145,603,069
G
Rara
retinoic acid receptor, alpha
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of RARA gene
CTD
PMID:16868089
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
G
Rb1
RB transcriptional corepressor 1
increases expression multiple interactions
ISO
Hydroxyurea results in increased expression of RB1 mRNA TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of RB1 mRNA]
CTD
PMID:27208086 PMID:29228353
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
G
Rbm4
RNA binding motif protein 4
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of RBM4 gene
CTD
PMID:16868089
NCBI chr 1:202,078,442...202,087,506
Ensembl chr 1:202,085,279...202,105,380
G
Rfx4
regulatory factor X4
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of RFX4 gene
CTD
PMID:16868089
NCBI chr 7:18,853,065...19,015,378
Ensembl chr 7:18,853,322...19,014,967
G
Rgs16
regulator of G-protein signaling 16
increases expression
ISO
Hydroxyurea results in increased expression of RGS16 mRNA
CTD
PMID:24211769
NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857
G
Rnf113a1
ring finger protein 113A1
decreases expression
ISO
Hydroxyurea results in decreased expression of RNF113A mRNA
CTD
PMID:24211769
NCBI chr X:116,427,941...116,429,164
Ensembl chr X:116,427,684...116,433,762
G
Rnf19a
ring finger protein 19A, RBR E3 ubiquitin protein ligase
decreases expression
ISO
Hydroxyurea results in decreased expression of RNF19A mRNA
CTD
PMID:12929121
NCBI chr 7:67,425,833...67,465,214
Ensembl chr 7:67,425,837...67,465,222
G
Rnf24
ring finger protein 24
decreases expression
ISO
Hydroxyurea results in decreased expression of RNF24 mRNA
CTD
PMID:33770205
NCBI chr 3:118,520,459...118,575,213
Ensembl chr 3:118,525,349...118,541,080
G
Rnf4
ring finger protein 4
decreases response to substance
EXP
RNF4 protein results in decreased susceptibility to Hydroxyurea
CTD
PMID:22661230
NCBI chr14:76,401,292...76,423,270
Ensembl chr14:76,401,299...76,422,566
G
Rpl22l1
ribosomal protein L22 like 1
decreases expression
ISO
Hydroxyurea results in decreased expression of RPL22L1 mRNA
CTD
PMID:12929121
NCBI chr 2:111,754,687...111,756,623
Ensembl chr 2:111,754,687...111,756,625
G
Rras
RAS related
increases expression
ISO
Hydroxyurea results in increased expression of RRAS mRNA
CTD
PMID:12929121
NCBI chr 1:95,500,582...95,504,362
Ensembl chr 1:95,500,566...95,504,357
G
Rrm2
ribonucleotide reductase regulatory subunit M2
decreases activity
ISO
Hydroxyurea results in decreased activity of RRM2 protein
CTD
PMID:22403396
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
G
Rrm2b
ribonucleotide reductase regulatory TP53 inducible subunit M2B
increases expression
ISO
Hydroxyurea results in increased expression of RRM2B mRNA
CTD
PMID:18647660
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
G
Runx1
RUNX family transcription factor 1
increases expression
ISO
Hydroxyurea results in increased expression of RUNX1 protein mutant form
CTD
PMID:16532439
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
G
Runx2
RUNX family transcription factor 2
affects expression
ISO
Hydroxyurea affects the expression of RUNX2 mRNA
CTD
PMID:24704097
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
G
Sesn1
sestrin 1
increases expression
ISO
Hydroxyurea results in increased expression of SESN1 mRNA
CTD
PMID:24211769
NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
G
Sgk1
serum/glucocorticoid regulated kinase 1
increases expression
ISO
Hydroxyurea results in increased expression of SGK1 mRNA
CTD
PMID:18647660
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
G
Slbp
stem-loop histone mRNA binding protein
decreases expression
ISO
Hydroxyurea results in decreased expression of SLBP mRNA
CTD
PMID:24211769
NCBI chr14:77,071,441...77,081,911
Ensembl chr14:77,071,632...77,081,906
G
Slc14a1
solute carrier family 14 member 1 (Kidd blood group)
affects transport increases uptake
ISO
SLC14A1 protein affects the transport of Hydroxyurea SLC14A1 protein results in increased uptake of Hydroxyurea
CTD
PMID:17506977 PMID:21256917
NCBI chr18:71,565,453...71,608,807
Ensembl chr18:71,565,454...71,595,146
G
Slc14a2
solute carrier family 14 member 2
increases uptake
ISO
SLC14A2 protein results in increased uptake of Hydroxyurea
CTD
PMID:21256917
NCBI chr18:71,612,460...72,039,462
Ensembl chr18:71,612,460...71,792,968
G
Slc16a12
solute carrier family 16, member 12
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of SLC16A12 gene
CTD
PMID:16868089
NCBI chr 1:232,184,004...232,262,170
Ensembl chr 1:232,185,907...232,262,141
G
Slc1a5
solute carrier family 1 member 5
decreases expression
ISO
Hydroxyurea results in decreased expression of SLC1A5 mRNA
CTD
PMID:24211769
NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
G
Slc22a4
solute carrier family 22 member 4
increases uptake
ISO
SLC22A4 protein results in increased uptake of Hydroxyurea
CTD
PMID:21256917
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
G
Slc22a5
solute carrier family 22 member 5
increases uptake
ISO
SLC22A5 protein results in increased uptake of Hydroxyurea
CTD
PMID:21256917
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
G
Slc6a4
solute carrier family 6 member 4
decreases expression
ISO
Hydroxyurea results in decreased expression of SLC6A4 mRNA
CTD
PMID:34748853
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
G
Slco1a4
solute carrier organic anion transporter family, member 1a4
increases uptake
ISO
SLCO1A2 protein results in increased uptake of Hydroxyurea
CTD
PMID:21256917
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
G
Slco1b2
solute carrier organic anion transporter family member 1B2
multiple interactions increases uptake
ISO
naringin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]
CTD
PMID:21256917
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
G
Smim14
small integral membrane protein 14
decreases expression
ISO
Hydroxyurea results in decreased expression of SMIM14 mRNA
CTD
PMID:33770205
NCBI chr14:42,783,361...42,829,762
Ensembl chr14:42,783,332...42,829,760
G
Snca
synuclein alpha
multiple interactions
ISO
Hydroxyurea promotes the reaction [SNCA protein mutant form results in increased susceptibility to ferrous chloride]; Hydroxyurea promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]
CTD
PMID:14535945
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
G
Spink4
serine peptidase inhibitor, Kazal type 4
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of SPINK4 gene
CTD
PMID:16868089
NCBI chr 5:56,043,936...56,064,841
Ensembl chr 5:55,981,624...56,064,795
G
Srxn1
sulfiredoxin 1
increases expression
ISO
Hydroxyurea results in increased expression of SRXN1 mRNA
CTD
PMID:22003191
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
G
Stk4
serine/threonine kinase 4
increases cleavage multiple interactions
ISO
Hydroxyurea results in increased cleavage of STK4 protein TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased cleavage of STK4 protein]
CTD
PMID:29228353
NCBI chr 3:152,745,958...152,827,747
Ensembl chr 3:152,745,681...152,827,744
G
Svop
SV2 related protein
increases expression
ISO
Hydroxyurea results in increased expression of SVOP mRNA
CTD
PMID:27208086
NCBI chr12:42,530,991...42,589,381
Ensembl chr12:42,531,032...42,590,572
G
Tap1
transporter 1, ATP binding cassette subfamily B member
increases expression
ISO
Hydroxyurea results in increased expression of TAP1 mRNA
CTD
PMID:27208086
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
G
Tbpl1
TATA-box binding protein like 1
affects localization
ISO
Hydroxyurea affects the localization of TBPL1 protein
CTD
PMID:17085973
NCBI chr 1:22,777,892...22,803,305
Ensembl chr 1:22,778,459...22,803,122 Ensembl chr 1:22,778,459...22,803,122
G
Tbx6
T-box transcription factor 6
decreases expression
ISO
Hydroxyurea results in decreased expression of TBX6 mRNA
CTD
PMID:29990529
NCBI chr 1:181,387,851...181,392,762
Ensembl chr 1:181,388,684...181,392,593
G
Tcrg
T cell receptor gamma chain
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of TCRG gene
CTD
PMID:16868089
NCBI chr17:45,622,041...45,666,123
G
Tfec
transcription factor EC
decreases expression
ISO
Hydroxyurea results in decreased expression of TFEC mRNA
CTD
PMID:24211769
NCBI chr 4:45,106,129...45,180,236
Ensembl chr 4:45,107,641...45,180,236
G
Tipin
timeless interacting protein
decreases expression
ISO
Hydroxyurea results in decreased expression of TIPIN mRNA
CTD
PMID:24211769
NCBI chr 8:64,780,813...64,801,358
Ensembl chr 8:64,780,828...64,801,352
G
Tmem185b
transmembrane protein 185B
decreases expression
ISO
Hydroxyurea results in decreased expression of TMEM185B mRNA
CTD
PMID:24211769
NCBI chr13:30,647,533...30,650,864
Ensembl chr13:30,647,482...30,650,858
G
Tmem250
transmembrane protein 250
increases expression
ISO
Hydroxyurea results in increased expression of TMEM250 mRNA
CTD
PMID:33770205
NCBI chr 3:8,962,657...8,966,349
Ensembl chr 3:8,962,657...8,966,349
G
Tmem69
transmembrane protein 69
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of TMEM69 gene
CTD
PMID:16868089
NCBI chr 5:130,004,888...130,008,466
Ensembl chr 5:130,004,901...130,010,655
G
Tnf
tumor necrosis factor
increases secretion
ISO
Hydroxyurea results in increased secretion of TNF protein
CTD
PMID:14965870
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tnfrsf10b
TNF receptor superfamily member 10b
increases expression
ISO
Hydroxyurea results in increased expression of TNFRSF10A mRNA
CTD
PMID:27208086
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
G
Top1
DNA topoisomerase I
decreases expression
ISO
Hydroxyurea results in decreased expression of TOP1 mRNA
CTD
PMID:12929121
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
G
Tor1a
torsin family 1, member A
decreases expression
ISO
Hydroxyurea results in decreased expression of TOR1A mRNA
CTD
PMID:24211769
NCBI chr 3:14,250,667...14,257,704
Ensembl chr 3:14,250,676...14,257,691
G
Tp53
tumor protein p53
multiple interactions increases expression affects response to substance increases phosphorylation
ISO
Hydroxyurea results in increased expression of and results in increased phosphorylation of TRP53 protein; Hydroxyurea results in increased phosphorylation of and results in increased activity of and affects the localization of TRP53 protein; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased cleavage of CASP3 protein]; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased cleavage of STK4 protein]; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of CDKN1A mRNA]; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of FAS mRNA]; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of PMAIP1 mRNA]; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of RB1 mRNA]; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of TRP53INP1 mRNA]; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of TRP73 mRNA]; TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased phosphorylation of H2AX protein] Hydroxyurea results in increased expression of TP53 protein; Hydroxyurea results in increased expression of TP53 protein modified form TRP53 affects the susceptibility to Hydroxyurea Hydroxyurea results in increased phosphorylation of TP53 protein
CTD
PMID:10978678 PMID:16005713 PMID:16356682 PMID:21840268 PMID:25125662 PMID:27208086 PMID:29228353 PMID:32466334 More...
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tp53inp1
tumor protein p53 inducible nuclear protein 1
increases expression multiple interactions
ISO
Hydroxyurea results in increased expression of TRP53INP1 mRNA; Hydroxyurea results in increased expression of TRP53INP1 protein TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of TRP53INP1 mRNA]
CTD
PMID:27208086 PMID:29228353
NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968
G
Tp63
tumor protein p63
decreases expression
ISO
Hydroxyurea results in decreased expression of TRP63 mRNA
CTD
PMID:29228353
NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398
G
Tp73
tumor protein p73
increases expression multiple interactions
ISO
Hydroxyurea results in increased expression of TRP73 mRNA TRP53 gene mutant form inhibits the reaction [Hydroxyurea results in increased expression of TRP73 mRNA]
CTD
PMID:29228353
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
G
Tpp2
tripeptidyl peptidase 2
affects localization
ISO
Hydroxyurea affects the localization of TPP2 protein
CTD
PMID:20643100
NCBI chr 9:46,046,712...46,128,157
Ensembl chr 9:46,046,632...46,128,157
G
Tradd
TNFRSF1A-associated via death domain
multiple interactions
ISO
Hydroxyurea promotes the reaction [Valproic Acid results in increased expression of TRADD protein]
CTD
PMID:17653085
NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638
G
Triap1
TP53 regulated inhibitor of apoptosis 1
increases expression
ISO
Hydroxyurea results in increased expression of TRIAP1 mRNA
CTD
PMID:18647660
NCBI chr12:41,267,534...41,270,053
Ensembl chr12:41,267,549...41,270,042
G
Trim32
tripartite motif-containing 32
decreases expression
ISO
Hydroxyurea results in decreased expression of TRIM32 mRNA
CTD
PMID:24211769
NCBI chr 5:79,005,139...79,016,615
Ensembl chr 5:78,999,389...79,022,018
G
Trim38
tripartite motif containing 38
decreases expression
ISO
Hydroxyurea results in decreased expression of TRIM38 mRNA
CTD
PMID:24211769
NCBI chr17:41,351,857...41,365,021
G
Trim68
tripartite motif containing 68
increases expression
ISO
Hydroxyurea results in increased expression of TRIM68 mRNA
CTD
PMID:12929121
NCBI chr 1:157,114,044...157,127,494
Ensembl chr 1:157,114,044...157,127,477
G
Ubac2
UBA domain containing 2
increases mutagenesis
ISO
Hydroxyurea results in increased mutagenesis of UBAC2 gene
CTD
PMID:16868089
NCBI chr15:98,960,139...99,107,795
Ensembl chr15:98,960,139...99,107,787
G
Ube2c
ubiquitin-conjugating enzyme E2C
decreases expression
ISO
Hydroxyurea results in decreased expression of UBE2C mRNA
CTD
PMID:17374387
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
G
Utp3
UTP3, small subunit processome component
decreases expression
ISO
Hydroxyurea results in decreased expression of UTP3 mRNA
CTD
PMID:24211769
NCBI chr14:19,515,716...19,517,370
Ensembl chr14:19,515,669...19,517,396
G
Wnt3a
Wnt family member 3A
decreases expression
ISO
Hydroxyurea results in decreased expression of WNT3A mRNA
CTD
PMID:29990529
NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324
G
Xpc
XPC complex subunit, DNA damage recognition and repair factor
increases expression
ISO
Hydroxyurea results in increased expression of XPC mRNA
CTD
PMID:18647660
NCBI chr 4:123,993,670...124,020,922
Ensembl chr 4:123,993,666...124,021,010
G
Xrcc4
X-ray repair cross complementing 4
decreases response to substance
ISO
XRCC4 results in decreased susceptibility to Hydroxyurea
CTD
PMID:21785230
NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808
G
Xrcc5
X-ray repair cross complementing 5
decreases expression increases mutagenesis
ISO
Hydroxyurea results in decreased expression of XRCC5 mRNA Hydroxyurea results in increased mutagenesis of XRCC5 gene
CTD
PMID:12929121 PMID:16868089
NCBI chr 9:73,955,216...74,044,020
Ensembl chr 9:73,955,216...74,044,018
G
Zbtb24
zinc finger and BTB domain containing 24
decreases expression
ISO
Hydroxyurea results in decreased expression of ZBTB24 mRNA
CTD
PMID:24211769
NCBI chr20:44,943,302...44,965,329
Ensembl chr20:44,947,297...44,963,963
G
Zfp280c
zinc finger protein 280C
decreases expression
ISO
Hydroxyurea results in decreased expression of ZNF280C mRNA
CTD
PMID:33770205
NCBI chr X:127,716,403...127,807,600
Ensembl chr X:127,717,983...127,779,825
G
Zfp365
zinc finger protein 365
increases expression
ISO
Hydroxyurea results in increased expression of ZFP365 mRNA
CTD
PMID:27208086
NCBI chr20:20,666,240...20,689,734
Ensembl chr20:20,666,240...20,691,238
G
Zfp385a
zinc finger protein 385A
increases expression
ISO
Hydroxyurea results in increased expression of ZFP385A mRNA
CTD
PMID:12929121
NCBI chr 7:134,448,914...134,475,548
Ensembl chr 7:134,448,921...134,475,548
G
Zfp94
zinc finger protein 94
decreases expression
ISO
Hydroxyurea results in decreased expression of ZNF45 mRNA
CTD
PMID:24211769
NCBI chr 1:79,858,188...79,879,702
Ensembl chr 1:79,859,180...79,879,612
G
Znf750
zinc finger protein 750
increases expression
ISO
Hydroxyurea results in increased expression of ZFP750 mRNA
CTD
PMID:27208086
NCBI chr10:106,772,162...106,781,186
Ensembl chr10:106,772,669...106,781,200
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all